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ABSTRACT
Postmenopausal osteoporosis is the most prevalent form of osteoporosis and results in fragility
fractures. Smoking is one of the major risk factors for osteoporosis and is known to aggravate
bone loss in postmenopausal women due to increased oxidative stress and inflammation. Dietbased interventions using berries have shown bone protective affects in animal studies partially
due to antioxidant and anti-inflammatory properties of their phenolic compounds. The goal of
this research was to determine the effects of antioxidant-rich fruits in the prevention of
postmenopausal bone loss. Our first study examined the dose dependent effects of blackberries in
preventing bone loss in an ovariectomized rat model of postmenopausal osteoporosis. Findings
from the animal study indicated that blackberries consumed at the level of 5% (w/w) and not
10% (w/w) may modestly prevent ovariectomy-induced bone loss. Next, we conducted a clinical
study to determine the effects of berries on bone loss. To explore this objective, postmenopausal
smokers were required to consume 45g of blackberries or blueberries for a 9 month period. Bone
mineral density of total body, and sites were determined at baseline and after 9 months. In
addition, biomarkers of bone metabolism and biomarkers of oxidative stress were measured. This
study found that blackberries and not blueberries modestly protected against smoking-induced
bone loss of the total body bone mineral density. No significant changes were noted on
biomarkers and other bone indices. The results of this research are inconclusive. Future studies
are necessary to confirm these findings and explore mechanisms by which berries may prevent
bone loss and effective doses in both postmenopausal smokers and nonsmokers.
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I.

INTRODUCTION

Osteoporosis is one of the most prevalent and debilitating bone diseases in the United
States (US) and worldwide 1. The disease impacts the quality of life of individuals affected and
results in enormous direct and indirect socioeconomic costs. Current annual cost for the
treatment of osteoporosis related fractures in the United States is estimated at $18 billion and
will increase to $25.3 billion by 20251.
Postmenopausal osteoporosis is the most prevalent form of osteoporosis 1. In the United
States, nearly half of all women over the age of 50 will suffer an osteoporosis-related fracture,
resulting in more than 1.5 million fractures a year 2. In addition to hormone deficiency, smoking
is considered a major risk factor in the pathogenesis of osteoporosis 3. According to 2010 Centers
for Disease Control and Prevention statistics, 21% of women aged 45-64 in the US are cigarette
smokers 4. Cigarette smoke contains over 1015 free radicals/g in what is known as the tar phase;
the smoke that is drawn into the mouth of an active smoker 5. These radicals have a life span of
few hours to months 5, and result in increased oxidative stress in smokers compared to nonsmokers. This is because long-term smoke exposure results in systemic oxidants-antioxidants
imbalance hence oxidative stress 6.
Oxidative stress in biological systems occurs due to an imbalance between the free
radicals and the body’s antioxidant mechanism 7. Higher levels of oxidative stress are evidenced
by elevated levels of products of lipid peroxidation such as isoprostanes and thiobarbituric acid
reactive substances (TBARS) 6. Also, depleted levels of plasma antioxidants including vitamins
A and C and reduced glutathione have been reported in smokers 6.
In women, heavy smoking throughout adult life has been reported to result in 5-10% less
bone by the age of 45-50 years, compared to non-smokers 8. Studies have demonstrated that
1

oxidants from cigarette smoke down regulate the expression of three important genes involved in
bone metabolism, osteocalcin, type 1 collagen and alkaline phosphatase. These genes are
important mediators of bone formation and essential for bone structure 9.
Although pharmacological options for prevention and treatment of postmenopausal
osteoporosis exist, the incidence of postmenopausal osteoporosis remains high. This is mainly
due to poor adherence to treatment, side effects associated with treatments, and poor access to
safe products 10. Intervention studies on postmenopausal osteoporosis are necessary to develop
alternative feasible nutritional strategies that women can embrace to reduce fracture risk. Natural
alternative therapies such as diet modification and phytotherapy are perceived to be safe and
have little to no side effects 11.
Consumption of a diet high in fruits and vegetables is known to improve serum oxidant
states in vivo, and reduce the incidence of cancer, vascular diseases, and other degenerative
diseases 12. Fruits and vegetables are rich sources of bioactive components including, vitamins,
minerals, fiber, and phytochemicals including phenolic compounds 13. Phenolic compounds are
widely studied for their strong superoxide scavenging capacity 12. In fact, these compounds
account for 80% of total antioxidant capacity in most fruits and vegetables 14. The antioxidant
capacities of certain phenolic compounds (e.g. flavonoids) may be stronger than vitamins C and
E based on molar concentrations 14.
Berries are a rich source of phenolic compounds plus several other nutrients including, B
vitamins, ascorbic acid (vitamin C), carotenoids (β carotene) and tocopherols, calcium, selenium,
and dietary fiber 15. Blueberries primarily contain the class of phenolic compounds known as
flavonoids, which includes: anthocyanins, catechin, epicatechin, quercetin, kaempferol,
myrecetin, and phenolic acids (e.g., gallic acid, p-hydroxybenzoic acid, chlorogenic, p-coumaric,
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caffeic, ferulic, and ellagic acids) 16, 17. Blackberries on the other hand contain chiefly
anthocyanins, flavonols, and hydrolyzable tannins or ellagitannins 18. Considering the abundance
of literature on blueberries compared to blackberries, a thorough review of blackberries was
written as part of this thesis paper.
Recently, the effects of berries and their extracts on bone health have been explored.
Animal studies have demonstrated that phenolic compounds from berries scavenge ROS formed
by phagocytes (i.e. monocytes, macrophages and neutrophils) 19 resulting in bone resorption 20.
Polyphenols such as chlorogenic acid, caffeic acid, and rutin in dried plum have prevented bone
loss in animal models by reducing oxidative stress biomarkers 21. Recently, blueberries and
blackberries have shown bone protective effects in an ovariectomized (OVX) rat model of
postmenopausal osteoporosis 22, 23. These animal studies provide some evidence of a positive
impact of antioxidant-rich berries on bone metabolism, paving way for clinical trials that fully
explore their effects in humans.
The overall goal of this research was to determine the effects of antioxidant-rich fruits in
the prevention of postmenopausal bone loss. To achieve this goal our objectives were as follows:
1) to examine the dose-dependent effects of blackberries in the prevention of bone loss
in an ovariectomized rat model of postmenopausal osteoporosis, and
2) to determine the role of antioxidant-rich blueberries and blackberries in prevention of
smoking-induced bone loss in postmenopausal women.
Hypothesis for the animal study was that antioxidant-rich blackberries will dosedependently prevent bone loss in an ovariectomized (OVX) rat model of postmenopausal
osteoporosis. For the clinical study, the hypothesis was that consumption of antioxidant rich
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blackberries or blueberries for nine months will prevent smoking-induced bone loss in
postmenopausal women.
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II.

LITERATURE REVIEW

OSTEOPOROSIS
Osteoporosis is a metabolic bone disease that affects the bone quality and density and is
characterized by low bone mass and microarchitectural deterioration of bone tissue. This leads to
porous bone, fragility and increased fracture risk 1. Osteoporosis progresses silently, and unless a
fracture occurs, the disease is mostly asymptomatic. The main areas of the body at risk of
fracture are the lumbar spine, hip, and wrist although fractures can occur on any bone in this
condition 2. The most common fractures on the lumbar spine are known as vertebral fractures.
Low grade vertebral fractures occur on disks and when they eventually compress, they become
compression fractures. Compression fractures are responsible for loss of height and deformities
such as kyphosis, or stooped posture, associated with osteoporosis 2. The lifetime risk of
vertebral fracture has been estimated to be 15.4% after age 45 years, although true risk is likely
to be higher. Hip fractures are the most debilitating, and contribute significantly to age-related
deaths. In fact, even with rehabilitation, only 30% of hip-fracture patients regain pre-fracture
function 3. Measurements of the bone mineral density at these three regions lumbar spine, hip,
and wrist are used as predictors of fracture risk. The FDA has approved some techniques for
measurement of bone mass and density based on their ability to predict fracture risk 1. These
include: central computed tomography (CT), peripheral CT which focuses on the forearm or tibia
and dual energy x-ray absorptiometry (DXA) which is used to measure BMD and BMC of total
body and necessary body regions. DXA is considered the gold standard technique for measuring
bone mass due to its accuracy and precision 1. The World Health Organization defines bone loss
according to stages of severity: osteoporosis as BMD greater than -2.5 standard deviations below
the young adult reference mean BMD and osteopenia as BMD between -1.5 and -2.5 standard
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deviations below the young adult reference mean BMD. Estimates from the National
Osteoporosis Foundation state that 10 million Americans are already afflicted with osteoporosis
and another 42 million individuals are osteopenic and at risk for osteoporosis-related fractures 2.
POSTMENOPAUSAL OSTEOPOROSIS
Postmenopausal osteoporosis, also known as primary osteoporosis, is the most common
form of osteoporosis. In the United States, a conservative estimate is that nearly half of all
women over the age of 50 will suffer an osteoporosis-related fracture, resulting in more than 1.5
million fractures a year2. Current annual cost for treatment of osteoporosis related fractures in the
United States is estimated at 18 billion 2. Due to the large population of aging baby boomers and
the fact that people are living longer, experts estimate that these costs will increase to $25.3
billion by 20252.
A woman is defined as postmenopausal if 12 consecutive months of amenorrhea is
confirmed without medical reasons. Before menopause sets in, women experience a premenopausal period known as the perimenopause stage. During perimenopause, ovarian
production of estrogen gradually declines 4. This decline eventually leads to a 90% reduction of
serum estradiol by the time a woman is confirmed to be menopausal 5. This loss of estrogen
causes a bone loss of about 5% for cancellous bone and 1 to 3% for cortical bone per year in
early postmenopausal women (1-5 years after menopause) 5, 6. In addition, during early
menopause, women loose approximately 3% of bone in the spine per year 7 accounting for 50%
of lifetime vertebral bone loss 7. In fact, 20 years into menopause, women lose up to 50% of
trabecular bone and 30% of cortical bone 6. It is now well understood that estrogen is essential
for bone resorption and formation process to remain coupled 7. The 90% reduction in serum
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estrogen in the early menopause rapidly increases bone turnover and the rate of resorption
without a matched increase in bone formation, hence irreversible bone loss 7.
There are other hormonal and environmental factors that affect skeletal health. Decreased
secretion of the growth hormone and inadequate or lack of physical activity may lead to impaired
osteoblast function and less bone formation resulting in bone loss 5. Also, environmental factors
such as a diet low in calcium intake in early years of life, low body weight at 1 year or at
maturity, delayed puberty, and early menopause may control an individual’s bone mass 7.
Furthermore, after menopause, bone loss may be accelerated by certain drugs such as
corticosteroids. Corticosteroids are medications that relieve inflammation and their actions
resemble certain hormones made by your own body. When taken long-term (more than 6
months) or at high doses, these drugs can cause bone loss that leads to osteoporosis and fractures
7

. These medications, also known as steroids and glucocorticoids may be used in the treatment

of many conditions including arthritis and asthma. Tumors of the pituitary gland or diseases such
as metabolic syndrome, diabetes and cancer have also been known to cause bone loss 7.
In summary, although there are many factors that may affect skeletal health, estrogen
deficiency plays a key role in postmenopausal bone loss, increasing bone turnover and the rate of
resorption without a matched increase in bone formation. This change results in an imbalance in
remodeling and irreversible bone loss 7. Major mechanisms by which estrogen deficiency leads
to bone loss are discussed later in this chapter.
THE OVARIECTOMIZED RAT MODEL OF POSTMENOPAUSAL
OSTEOPOROSIS
The FDA requires that potential agents proposed for any human therapy are evaluated in
animal models 8. Previous and current research assures the suitability of the ovariectomized
8

(OVX) rat in demonstrating the efficacy and safety of postmenopausal-related therapies before
use in humans 8. Ovariectomy in young but skeletally mature rats makes the rat’s sex-hormone
deficient, and stimulates accelerated loss of bone that is similar to what occurs in women
following menopause 9. Investigations have found the OVX rat model mimics postmenopausal
cancellous bone loss when studies are conducted in less than 12 months and optimally within 6
months of life 8. OVX rat model is reported to undergo rapid loss of trabecular bone mass and
strength after ovariectomy 10, 11. A study by Laib and others reported a 40% rapid decrease in
bone volume and a two-fold decrease in tibia cancellous bone volume after ovariectomy 11. Other
reported similarities in OVX rat model and postmenopausal women include: increased resorption
rate compared to formation rate and an initial rapid phase of bone loss followed by a slower
phase. Both also report more cancellous than cortical bone loss, and decreased intestinal
absorption of calcium. Another similarity is that in both, obesity provides protection against bone
loss. Finally, they exhibit similar treatment effects after administration of exercise, hormones
such as estrogen, parathyroid hormone and calcitonin, and drug therapies tamoxifen, and
bisphosphonates 9.
There are disadvantages linked to the use of the OVX-rat as a model of postmenopausal
osteoporosis. These include the fact that long bone of the rat grows longitudinally briefly after
ovariectomy which can slightly affect results, however the use of 9-12 month old rats lessens the
effects of this disadvantage 12. Secondly, haversian systems in rats are either lacking or poorly
developed unlike the well-developed haversian system in humans. 12. Finally, the OVX rat model
does not experience fragility fractures as seen in humans 13. Despite these limitations, the OVX
rat model is a suitable rat model to study postmenopausal osteoporosis 8.
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SKELETAL SYSTEM
The adult human skeleton is a highly specialized organ comprised of 206 bones, each
formed by a process known as modeling, and every bone constantly being renewed in a process
known as remodeling 14. The skeleton serves three main functions although depending on
position each bone may serve more than one specific function including, 1) mechanical support
and levers for muscles, 2) protection of vital organs, and 3) repository for calcium and
phosphorous 15. Bones are also rich sources of growth factors and cytokines that may have both
inhibitory and stimulatory effects on bone functions 14. Bone may be classified according to
process of formation into flat bones and long bones. Flat bones are such as the skull, mandible,
and scapula while the long bones include the femur, tibia, and radius 14. Structurally, bone tissue
is divided into trabecular bone and compact bone 16. Trabecular bone is also known as spongy or
cancellous bone has 75%-95% porosity and is found in the cuboidal bones such as flat bones and
the ends of long bones. The pores are interconnected and filled with marrow. Compact bone is
also called cortical bone and its porosity is only 5%-10%. Cortical bone forms a cortex or shell
around vertebral bodies and other spongy bones and also is found in the shafts of long bones.
The pores in the cortical bone consist of three categories of spaces: 1) Haversian canals that are
about 50μm in diameter and contain capillaries and nerves, 2) Volkmann’s canals are transverse
canals that connect Haversian canals to each other and also contain blood vessels, and 3)
Resorption cavities which are more temporal in nature and are created by osteoclasts in the
process of bone remodeling 16. In terms of function, although there may be differences due to
species or situation, cancellous bone is considered to be more metabolically active than cortical
bone, which largely serves a mechanical role 14.
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Mature bone has an outer fibrous sheath known as the periosteum, and the inner surface
which is in direct contact with the marrow known as the endosteum. Periosteum is made of
connective tissue and it covers all bone surfaces except at joints where the articular cartilage
lines the joints. The periosteum contains bone cells, nerves and blood vessels to ensure
nourishment, and is held strongly by collagenous fibers known as Sharpeys’fibers that penetrate
the bone tissue. The endosteum is a membranous sheath well served with blood vessels and bone
cells and covers the surface of the cancellous bone and lines Volkmann’s canals 14.
BONE TISSUE
Bone tissue is composed of three primary components- water, organic matrix (largely
collagen), and minerals 17. These components are commonly categorized into: collagen,
hydroxyapatite mineral, small amounts of proteoglycans, noncollagenous proteins, and water.
Collagen is a rigid, rod-like protein molecule composed of two alpha chains consisting of
repeating amino acids with glycine in every third position and a high content of proline and
lysine. These chains form a triple helix that is stabilized by the hydroxylation of proline and
lysine residues by ascorbic acid 18. Although several types of collagen are identified in animals,
the predominant collagen in bone is type I. Collagen is found in tendons, skin, and ligaments,
and has great structural properties. Collagen can spontaneously organize itself into strong fibers
which give bone flexibility and tensile strength. In addition, collagen provides the nucleation of
bone mineral crystals, which account for the rigidity and compressive strength in bone 16. The
inorganic mineral of bone almost entirely consists of hydroxyapatite crystals that contain
carbonate, citrate, sodium, and magnesium 17. The crystals are rods or hexagonal plates.
Proteoglycans are proteins that carry sulfated carbohydrate component known as
glycosaminoglycan attached to them 17. Glycosaminoglycans are important binding sites for
11

fibroblast, endothelial growth factors and extracellular matrix proteins such as fibronectin and
interstitial collagens 17. Osteocalcin which is important in new bone mineralization is the most
abundant noncollagenous protein 16. Bone marrow is found in the spaces in the trabeculae of all
bones. It contains red blood cells, white blood cells, and platelets providing a continuous supply
of oxygen and nourishment ensuring the tissue’s demands for immunity and coagulation are
adequately met 16, 19.
BONE CELLULAR COMPONENTS
The formation and maintenance of bone extracellular matrix is carried out by four major
cellular components- osteoclasts, osteoblasts, and osteocytes and bone lining cells 16. According
to Riasz, osteoclasts and osteoblasts are derived from multipotent hematopoietic cells and not
monocyte/macrophage lineage as previously thought 20. Osteoclasts differentiate as
mononucleated cells that express tartrate resistant acid phosphatase (TRAP) and calcitonin
receptors even before fusion occurs 20. Mature multinucleated osteoclasts erode their way
through bone by demineralizing adjacent bone with acids and then dissolving its collagen with
enzymes 16.On the other hand osteoblasts are mononucleated bone forming cells akin to the
fibroblasts, which are cells that produce structural molecules in other tissues. Osteoblasts are
responsible for the production of osteoid, the organic portion of the bone matrix. The boundary
that separates osteoid and calcified bone is known as the calcification or mineralization front 16.
Osteocytes are former osteoblasts that become buried in bone and sits in the cavities called
lacunae. These cells communicate among themselves and to active osteoblasts via tunnels known
as canaliculi or little canals 16. Bone lining cells are retired osteoblasts that escaped being buried
in newly formed bone and are found on the surface after bone formation. These cells are
flattened against the bone surface with gaps in between them and via these gap-junctions
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maintain communication with osteocytes 16. Both lining cells and osteocytes work to transfer
minerals into and out of the bone 21 and are important for sensing mechanical strain 16.
The development and differentiation of cellular components is controlled by growth
factors, cytokines, and systemic hormones 22. These growth hormones and cytokines are
produced in the bone marrow microenvironment. It is proposed that these processes occur
through positive and negative feedback loops, cascades formed by growth hormones and
cytokines, and via hormonal control and/ or action of local mediators 6.
Several cytokines and local regulatory factors influence hematopoiesis and affect
osteoclast development 22. These cytokines include interleukin 1(IL-1), interleukin 11 (IL-11),
interleukin 3 (IL-3), interleukin 6 (IL-6), tumor necrosis factor –alpha (TNF-α) and granulocyte
macrophage-colony stimulating factor (M-CSF). The cytokines that inhibit osteoclast
development and in turn bone resorption include interferon-γ, IL13, IL-4, IL-10, and IL-18 20.
Mesenchymal stem cells (MSCs) differentiate into functional osteoblasts capable of bone
formation through a complex multistep process 20. Commitment of MSCs to form osteoblasts,
osteoblastogenesis, is orchestrated by bone morphogenetic proteins (BMPs) 23. Osteoblast
differentiation is also influenced by several factors, including transforming growth factor β
(TGFβ), platelet-derived growth-factor (PDGF), insulin-like growth factors (IGFs), and members
of the fibroblast growth factor (FGF) family and peptide hormones (e.g. parathyroid hormone
PTH) 20.
MODELING AND REMODELING
Modeling is the process responsible for skeletal change in size and shape during growth
and development of bones. Modeling occurs as a result of independent action of osteoblasts and
osteoclasts while remodeling is defined as resorption and formation that occur at the same site 20.
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According to Martin et al. modeling and remodeling are distinguished from one another in four
main ways: 1) modeling at a particular site is continuous and prolonged, while remodeling is
more episodic with a precise beginning and end, 2) remodeling occurs throughout life although
the process is slower after growth stops, 3) modeling involves independent actions of osteoclasts
and osteoblasts while remodeling involves a series of coupled actions of osteoclastic and
osteoblastic cells, and 4) modeling results in altered bone size, shape, or both while remodeling
has no effect on shape or size 16. Bone formation dominates during periods of skeletal growth
such as during childhood and adolescence, but once the skeleton has reached maturity, new bone
tissue is formed through remodeling 14. The rate of remodeling is age dependent although there is
evidence that remodeling results in complete regeneration of the skeletal tissue every 10 years 22.
Remodeling is considered a vital process because longitudinal growth does not give rise to bone
of correct geometry. Moreover, during growth each child loads on his or her skeleton differently,
thus requiring customization. On the other hand, remodeling repairs microscopic damages to the
skeleton and prevents fatigue fracture and maintains calcium homeostasis 16. At the beginning of
the third decade of life, there is a steady decrease in bone mass due to the higher rate of
resorption. Bone remodeling becomes uncoupled and the osteoclast activity becomes greater than
the osteoblast activity resulting in bone loss 20.
SYSTEMIC HORMONES REGULATING BONE METABOLISM
A large number of local and systemic factors activate and regulate functions of the
skeleton. Two major calcium-regulating hormones, the parathyroid hormone (PTH) secreted by
the parathyroid gland and dihydroxycholecalciferol (1, 25 (OH)2 D) control bone remodeling 24.
Parathyroid hormone regulates bone remodeling by enhancing mobilization of calcium from the
skeleton 19. The active hormonal vitamin D, 1, 25 (OH)2 D or calcitriol, is critical for optimal
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intestinal absorption of calcium and phosphorus and maintaining skeletal growth and
development 25. Calcitriol also exerts a tonic inhibitory effect on PTH synthesis 26. Calcitonin, a
hormone produced by cells in the thyroid gland to oppose effects of PTH, appears to play a lesser
role in regulating bone turnover even although it inhibits bone resorption by acting directly on
the osteoclasts 27.The growth hormone is another systemic hormone which increases both
circulating and local levels of insulin-like growth factor–I (IGF-I). Growth hormone (GH) plays
a role in bone modeling and remodeling, and directly stimulates cartilage cell proliferation. GH
and IGF stimulate both formation and resorption and determine skeletal size before epiphyseal
closure 24.
Sex hormones are critical in the regulation of skeletal development and bone remodeling
24

. Both estrogen and androgen hormone receptors are found in bone cells 27. Estrogens acts on

the skeleton through direct effects on cartilage and by its effects on other hematopoietic cell
lineages. Estrogen deficiency is believed to be the single most important factor in pathogenesis
of postmenopausal osteoporosis 24.
ESTROGEN AND BONE
Estrogen regulates the cytokine receptor activator of nuclear factor kappa B ligand
(RANKL) which acts directly on the hematopoietic lineage of osteoclasts resulting in osteoclast
recruitment and activity 24. RANKL is expressed on the surfaces of bone marrow stromal or
osteoblast precursor cells, T-cells, and B-cells 28. Receptor activator of nuclear factor for kappa
B (RANK) is its cognate receptor found on osteoclast lineage cells 29. The binding of RANKL to
RANK is essential in the formation, development, and function of osteoclasts, and suppresses
their apoptosis 24. RANKL action is opposed by osteoprotegerin (OPG), a neutralizing soluble
antagonistic receptor, produced by osteoblasts to bind to RANKL and ensure a balance between
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bone loss and formation. The RANKL/RANK/OPG regulatory system is vital in osteoclast
formation and function and is responsible for the antiresorptive role of estrogen 28. After
postmenopausal stage, RANKL production is increased and/or OPG expression is decreased
resulting in bone loss 30.
Expression of RANKL and OPG is also influenced by PTH, vitamins, and other
molecules. For instance, RANKL production is increased while OPG is inhibited by PTH and
glucocorticoid 31. Vitamin K is also reported to modulate osteoblastogenesis and
osteoclastogenesis in bone marrow cells via the RANKL pathway 32. Hormonal 1, 25-(OH)2 D
enhances RANKL expression without any effect on OPG 33. Other factors include tumor growth
factor β (TGF β) that amplifies OPG production while IFN-γ suppresses RANKL induced
osteoclastogenesis 34.
In addition, estrogen affects bone formation by prolonging the lifespan of the osteoblast
through inhibition of osteoblast apoptosis at the cellular level 35. Estrogen prefers the
development of osteoblasts to adipocytes from their common precursor cells 36. Kousteni and
colleagues demonstrated that estrogen inhibits apoptosis of osteocytes in the OVX rat model 35.
Since osteocytes play a critical role in sensing mechanical loading, a reduction in the number of
osteocytes may result in bone loss similar to that found in weightless conditions 37.
INFLAMMATION AND BONE LOSS
Inflammation is a normal immune response stimulated by pro-inflammatory cytokines
and is a protective mechanism against invading microorganisms and infectious agents 38.
However, excessive and prolonged inflammation may cause extensive tissue and organ damage
and even death due to septic shock 38. The link between bone loss and inflammation is that proinflammatory factors TNF-α, IL-1, IL-6, and ROS also function as bone resorbing cytokines.
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Nuclear factor kappa B (NF-kappa B) is a transcription factor that is important in modifying the
intracellular regulation of the immune response, inflammation, and cell cycle coordination 39.
NF-kB also functions as a regulator for the expression of TNF-α, interleukin (IL)-1, and
interleukin (IL)-6 among other important pro-inflammatory cytokines 39. Conditions associated
with prolonged inflammation result in chronic elevation of these factors, TNF-α, IL-1, IL-6, and
increased ROS resulting in bone loss. Examples of conditions associated with bone loss include
periodontal disease 40, autoimmune diseases, rheumatoid arthritis multiple sclerosis, and
inflammatory bowel disease 41.
ROLE OF ESTROGEN IN INFLAMMATION
There are functional estrogen receptors on osteoblasts and osteoclasts which when
activated block the synthesis of pro-inflammatory and bone resorbing cytokines IL-6, IL-1, and
TNF-α 42 Estrogen deficiency, therefore, creates an environment for increased inflammatory
mediators and results in accelerated bone turnover characterized by increased bone resorption
compared to bone formation42, 43. Reactive oxygen species (ROS) (e.g.O2-, H2O2, NOO-)
produced in states of inflammation, further enhance inflammation through the activation and
phosphorylation of stress kinases. c-Jun N terminal kinase 44, and transcription factors such as
NF-ĸB and activator protein-1 (AP-1) 45.
ESTROGEN, OXIDATIVE STATUS AND BONE LOSS
Estrogen is an efficient scavenger of free radicals generated in both the aqueous and the
lipophilic phases, and its antioxidant activity has been found to be up to 2.5 times that of vitamin
C and vitamin E 46. Estrogen’s antioxidant effects are attributed to the aromatic hydroxyphenol
structure of the A ring although estrogen receptors may mediate some antioxidant action as well
47

. Recently, it also has been suggested that estrogen augments intracellular oxidant defenses
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lowering the concentration of ROS within cells 48. Estrogen inhibits bone resorption by
suppressing the production of cytokines IL-1, IL-6, M-CSF, prostaglandin (PG) E2, and TNF-α,
which are stimulators of ROS production 6.
Experiments using ovariectomized animal models have demonstrated that in states of
depleted intracellular antioxidants, mainly glutathione and thioredoxin, osteoclast activity
increases via up-regulation of TNF-α 49. TNF-α is a pro-inflammatory cytokine associated with
activation of inflammation and osteoclastic activity 49. In estrogen-deficient animal models,
administration of antioxidants (e.g. N-acetyl cysteine or ascorbic acid) has shown to increase
levels of glutathione and thioredoxin, and decrease TNF-α production 48 Cell culture experiments
have also shown that administration of glutathione and thioredoxin in osteoclasts protects against
bone loss during estrogen deficiency 48. For example, to investigate the effects of ovariectomy
and estrogen on oxidant defenses in bone, Lean and colleagues found that administering a single
dose of 17-β estradiol (10μg/kg) subcutaneously- the standard replacement dose for rodents
normalized previously low levels of thiol antioxidant system within 24 hours 48. This experiment
demonstrates that estrogen increases oxidant defenses and its deficiency may directly or
indirectly promote bone resorption 48.
ESTROGEN, CALCIUM ABSORPTION AND PTH IN BONE HEALTH
Estrogen plays an important role in calcium absorption in the gut 50 and its reabsorption
in the kidney 51. Reduced estrogen production leads to both decreased intestinal calcium
absorption and high loses of calcium in urine 51. This provides evidence that estrogen regulates
renal tubular calcium absorption 51. Intestinal mucosal cells contain estrogen receptors that have
been shown to respond to 17-β-estradiol by enhancing calcium transportation 52. The effect of
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low estrogen on calcium absorption in the intestines and the increased loss through the kidneys
can each account for late phase bone loss in postmenopausal women 53.
Estrogen indirectly effects bone resorption through its effect on PTH secretions. The slow phase
of bone loss in postmenopausal women is linked to both an increase in PTH levels and actions,
and to senescence of osteoblasts. These factors are similar in both men and women age 60 and
above and are attributed to calcium deficiency. Calcium deficiency is as a result of reduced
absorption in the intestines and less reabsorption in the kidneys due to organ atrophy. Bone loss
may also be attributed to a vitamin D deficiency due to decreased 1-alpha-hydroxylase activity in
the kidneys in women who do not get enough sunlight54, 55
SMOKING AND BONE LOSS
Tobacco use is the number one preventable cause of mortality and morbidity in the
United States (CDC 2009). Cigarette smoking is a risk factor for cardiovascular diseases 56,
several neoplasmic conditions including cancer of the throat, tongue, lung, and bladder 57.
Smoking is also a major risk factor for osteoporosis 58. As mentioned earlier, radicals inhaled
from cigarette smoke down regulate the expression of three important genes: osteocalcin, type 1
collagen, and alkaline phosphatase which are key mediators of bone formation and structure 59.
Moreover, there are over 150 known toxic compounds that have been found in cigarettes,
although nicotine is the main chemical substance and one that leads to addiction 59. Nicotine is
known to alter bone metabolism, increase fracture risk, and compromise healing after a fracture
by delaying bone callous formation and remodeling 60. Tobacco use is also implicated in poor
spinal fusion 61, 62. Chronic administration of nicotine has been linked to low bone mineral
density, low bone mineral content, and shorter bones 63.
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The following are summaries of human studies that report the negative effects of
cigarette smoking on bone.
A population-based cohort study of subjects aged 60 years and older reported that
smoking levels recorded 16–18 years earlier were accurately indicative of lower BMD at the hip
in both men and women even after adjustment for multiple confounders including age, exercise,
alcohol use, body mass index and hormone use 64. Krall and Dawson-Hughes 65 also found that
bone density at the radius of the wrist was inversely related to pack-years of smoking exposure in
postmenopausal women, after controlling for confounders such as BMI and years after
menopause 65. A large Danish study of 2015 postmenopausal women aged 45–58 years revealed
significant negative associations between smoking and bone mass in the lumbar spine, femoral
neck, and total body. This study reported a 3% deficit at the femoral neck in current smokers
when their BMD was compared with non-smokers 66. Additionally, smoking was correlated with
a 4% lower BMD at the spine compared with non-smokers in a three year study of 153 early
postmenopausal women 67. Similarly, a Southern Californian longitudinal study of 8600
postmenopausal women found that current smokers had an increased hip fracture risk compared
to those who had never smoked 68.
Effects of smoking on bone health are best summarized using three meta-analyses
published over the past 10 years 69. The first by Wong and colleagues gathered 29 published
cross-sectional studies examining 2156 smokers and 9705 non-smokers, and 19 cohort and casecontrol studies representing 3889 hip fractures and reported the following:

69

: (i) in women,

smoking accounts for one in eight hip fractures; (ii) the relative risk of hip fracture in smokers
compared with non-smokers is strongly associated with age, thus the longer one smokes the
higher the risk for fracture; (iii) the difference in BMD at the femoral neck, radius, and heel bone

20

(calcaneus) in smokers compared to non-smokers increased with age and BMD of smokers fell
2% more than that of non-smokers every 10 years; (iv) smoking has a direct effect on BMD that
cannot be attributed to variations in body mass, menopausal history, exercise levels, or hormone
therapy 69.
The second meta-analyses by Ward and Klesges pooled data from 86 studies representing
40753 subjects 70. The results were as follows: (i) smokers had less bone mass at hip, lumbar
spine, forearm and calcaneus; (ii) smoking cessation had a beneficial effect on bone mass, with
BMD being between life-long non-smokers or current smokers; (iii) smoking increased the
lifetime risk of hip fracture by 31% in women and 40% in men, and of lumbar spine by 13% in
females and 32% in males; and (iv) smoking accounted for up to 10% of all hip fractures. These
results mean that an estimated 34000 hip fractures per year in the United States alone are
attributable to smoking 70.
The third and most recent meta-analysis of 10 prospective cohort studies in five
continents examined 59232 subjects and reported that, smoking increased fracture risk by 25%
when risk in smokers was compared with the risk in never-smokers. The highest risk reported
was for hip fracture. Secondly, smoking-associated fracture risk was related to body mass index
but the effects were not significant 69.
MECHANISMS BY WHICH SMOKING CAUSES BONE LOSS
Smoking and bone loss has been investigated and some mechanisms by which it causes
bone loss have been identified as: 1) reduced active vitamin D in plasma, 2) malabsorption of
calcium, and 3) oxidative stress and 4) inflammation.
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Reduced Active Vitamin D in Plasma
There is evidence that high concentration of nicotine in plasma is associated with low 1, 25 (OH)
2D levels in animal models 71. Fung and colleagues reported a 25% decrease in serum levels of
1, 25 (OH) 2D when seven month old female rats were treated with 4.5mg/kg/day of nicotine.
The dose was administered via subcutaneous osmotic pumps for 90 days and results compared to
both control group and low nicotine group (3mg/kg/day) 71. The role of vitamin D and calcium in
bone health is discussed earlier and cannot be over emphasized.

Malabsorption of calcium
In humans, tobacco use is associated with decreased calcium absorption 65. Since
restoration of systemic plasma calcium balance is extremely crucial, the body increases retention
or withdraws calcium from the skeleton 72. Long periods of calcium insufficiency thus cause
bone loss since bone resorption will be higher than formation. The importance of calcium in
bone metabolism is also discussed earlier in this paper.

Oxidative stress
Studies have shown that long-term smoke exposure can result in systemic oxidantsantioxidants imbalance evidenced by increased products of lipid peroxidation such as
isoprostanes and thiobarbituric acid reactive substances (TBARS) (indices of lipid peroxidation
and oxidative stress), and depleted levels of plasma antioxidants including vitamin A and C and
GSH related antioxidants in plasma of smokers 73. The major free oxygen radicals or reactive
oxygen species (ROS) responsible for oxidative stress in biological systems are hydroxyl radicals
(OH·), peroxide anions (O·2- ), hydrogen peroxide (H2O2), and nitric oxide (NO) 74; smoking is
an additional source of radicals 75. These radicals account for oxidation of specific enzymes,
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proteins, lipid peroxidation, and DNA causing cell and tissue damage 74. Damaging effects of
ROS are mitigated by endogenous antioxidant enzymes such as superoxide dismutase (SOD),
glutathione peroxidase (GPx), and catalase 49 as well as by dietary antioxidants 76. Aged
osteoporotic women are reported to have decreased plasma antioxidants and tend to benefit from
dietary antioxidants such as vitamin C. Vitamin C supplementation is known to improve BMD in
postmenopausal women 77.
Free radicals such as NO from cigarette smoke activate NF-kappa B which is oxidative
stress-responsive transcription factor that induces bone resorption 78. Additionally, H2O2 is
known to inhibit differentiation markers in osteoblastic cells in marrow stromal cells modifying
differentiation of vascular and bone cells 79. Rothem et al reported lowered osteoblastic
proliferation and induce cell death when osteoblast-like cells (MG63) are incubated for 72 h in
levels of nicotine similar to that of habitual cigarette smokers 59. Furthermore, smokeless tobacco
extracts and nicotine in isolation have also been reported to suppress the growth of osteoblastlike cells in vitro 80 and decrease collagen synthesis 81.

Inflammation
In addition to oxidative stress, cigarette smoke causes systemic inflammation. Serum
levels of pro-inflammatory and bone resorbing cytokines IL-1 and IL-6 were reported to be
elevated in 21 three-month old male Sprague-Dawley rats treated with 7mg/kg/ body weight of
nicotine. The study also reported decreased trabecular bone volume and thickness at metaphyseal
region of left femurs, and decreased mineral appositional rate and bone formation rate 82.
Population-based studies have consistently reported a low-grade systemic inflammatory state in
smokers 83, 84. This inflammatory state in humans is characterized by increased circulatory
inflammatory mediators such as acute phase proteins and pro-inflammatory cytokines, C-reactive
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protein (CRP), fibrinogen, and interleukin-6, as well as increased white blood cell count (WBC)
73

. Studies such as the large-scale NHANES III study using 7,685 subjects, confirmed systemic

inflammation and revealed a strong independent dose-response relationship between cigarette
smoking and elevated levels of CRP, fibrinogen, and blood leukocytes 85. Another study that
analyzed data on 4,187 smokers, 4,791 former smokers, and 8,375 never-smokers and adjusted
for cofactors reported a dose-effect relationship between the number of cigarette smoked per day
and plasma fibrinogen concentrations 86, 87. Biomarkers such as urinary 8-iso-PGF2α, a major F2isoprostane, plasma GPx, and enzymatic SOD are reliable in vivo biomarkers of oxidative stress
and inflammation 77. A Swedish study involving 48 women and 53 men aged between 22-85
years reported that high urinary concentration of 8-iso-prostaglandin-F2α (8-iso-PGF2α) were
significantly correlated with low BMD of total body, lumbar spine, and heel 88.
TREATMENT OPTIONS FOR POSTMENOPAUSAL OSTEOPOROSIS
Osteoporosis medications fall into two categories: the antiresorptive medications that
slow the breakdown of bone and the anabolic treatments that help build bone. These medications
work with the body systems to protect bone mineral density and reduce the risk of fractures.
Currently, teriparatide is the only Food and Drug Administration (FDA) approved anabolic
medication available. Several FDA approved antiresorptive drugs are available and include
bisphosphonates, calcitonin, estrogen therapy/hormone therapy, and selective estrogen receptor
modulators (SERMs). These treatments have risks associated with their use, but all are geared
towards elimination or reduction of fracture risk 1. Selected approved therapies are discussed
below.
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Raloxifene
Raloxifene was approved for women only and is taken as an oral tablet daily for
treatment of osteoporosis. It is a drug derived from benzothiophene and is a SERM that comes in
a brand name Evista ®. SERMs represent a class of drugs that act as either estrogen receptor
agonists or antagonists in a tissue-selective manner 89. This pharmacologic profile of raloxifene
enables it to act by demonstrating estrogen-like effects on the skeleton and cardiovascular
system, and anti-estrogen effects on the breast and endometrium 90. In study a large human study,
7,705 postmenopausal women aged 31–80 years with osteoporosis; raloxifene was successful in
increasing lumbar spine and femoral neck BMD by 2–3%, while reducing the risk of vertebral
fractures by 30%–50%. Additionally, the drug decreased the incidence of breast cancer 91. Side
effects associated with the use of raloxifene include: increased risk for blood clots in the leg
veins and/or the lungs, increased hot flashes, leg cramps, and fluid retention 89.

Estrogen therapy
Estrogen therapy (ET) is administration of estrogen hormone alone as opposed to
hormone therapy (HT) which refers to estrogen with progesterone hormone therapy. Estrogen
used in many clinical trials may be conjugated equine estrogen, estradiol, estrone, esterified
estrogen, ethinyl-estradiol, and mestranol. Estrogen replacement is used in the treatment of bone
loss prevention of fractures risks 53 and increase in bone mass of the spine, hip, and total body1.
Therapies that use estrogen either target estrogen receptors directly or increase the diminishing
hormone level. As discussed earlier, estrogen favors bone formation by up-regulating osteoblast
activity and suppressing osteoclast activity. Estrogen increases synthesis of growth factors in
osteoblasts if administered in high doses and may increase mean wall thickness and other
histomorphometric indices of osteoblast activity in humans 92. In a Framingham cohort study that
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evaluated effects of hypogonadism and estradiol levels on BMD in men and women, estradiol
levels were strongly correlated with BMD at forearm, spine, and hip 93. However, while estrogen
can prevent osteoporosis in postmenopausal women, it also increases the risk of other health
problems. Estrogen therapy use is associated with possible estrogen-dependent tumors such as
breast cancer, stroke, ischemic attack, pulmonary embolus, deep vein thrombosis, or complex
hyperplasia 94.

Parathyroid hormone (PTH)
Parathyroid hormone is approved for the treatment of osteoporosis in both women and
men who are at particularly high risk for fractures, including subjects who are younger than age
65 and have low bone mineral density measurements (T scores ≤3.5) 95. Teriparatide
recombinant human PTH 1–34 (contains the first 34 amino acids of human PTH) 96and is
currently the only FDA approved in the first in a class of osteoporosis medications called
anabolics. Teriparatide is available in a brand name Forteo® and taken as a daily injection. The
action of PTH on bone requires the presence and contact with a combination of several
specialized cells including, bone marrow stromal cells, and hematopoietic precursors of
osteoclasts, mature osteoclasts and osteoblasts and works to form new bone 97. PTH enhances the
formation of trabecular bone when administered intermittently, but not chronically 98. In fact
certain dosages and continuous administration of PTH are associated with bone resorption. The
results of large study in which, 1637 postmenopausal osteoporotic women were receiving PTH
indicated for two years demonstrated that PTH reduced fracture risk by 65% and increased
vertebral lumbar spine bone mineral density by 9%–13% 99. Teriparatide therapy is not
recommended for more than 2 years since longer use may induce osteosarcoma as observed in a
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rat model of carcinogenicity 95 Side effects associated with PTH use include: headache,
hypercalcemia, dizziness, leg cramps, marrow fibrosis, tunneling resorption, and nausea 100.

Bisphosphonates
Bisphosphonates are compounds derived from pyrophosphate. The drugs in this class are
antiresorptive and act by slowing down the breakdown of bone by inhibiting hydroxyapatite
formation 3. Other mechanisms by which bisphosphonates slow bone loss include initiation of
osteoclast apoptosis 101, suppression of protein tyrosine phosphatases 102 and disruption of the
formation of cytoskeletal actin-ring in polarized resorbing osteoclasts 103.Osteoporosis drugs
available in this class are alendronate (Fosamax®), ibandronate (boniva®), risedronate
(Actonel®)and zoledronic acid (Reclast®). Despite proven efficacy, regular administration of
bisphosphonates is known to cause gastrointestinal problems such as upset stomach, diarrhea,
pain in arms and legs, dysphagia, esophageal and stomach ulcers 104.

Calcitonin
Calcitonin is a polypeptide hormone that has been used to treat osteoporosis and other
diseases involving accelerated bone turnover for over 25 years 105. In our bodies, calcitonin is
produced in the C cells of the thyroid 27 and salmon calcitonin is clinically administered for
treatment of osteoporosis 105. This hormone acts on the osteoclasts by inhibiting the
differentiation of osteoclast precursors 106 and suppressing the proliferation of progenitor cells
106

. Several controlled clinical studies have demonstrated that calcitonin is an antiresorptive

hormone that preserves or increases bone mineral density (BMD) and reduce the risk of vertebral
fractures. An added advantage of calcitonin is its direct analgesic effect. Calcitonin has been
demonstrated to be clinically useful in improving pain, from the acute vertebral fractures of
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osteoporosis and other sources of musculoskeletal pain unlike any other therapy 105. Calcitonin is
available in two brand names, Fortical® and Miacalcin®).
NUTRIENTS AND BONE METABOLISM
Protein
Protein is important in bone formation although there is a possibility that animal protein
has deleterious bone resorbing effects when consumed in excess 107. The main functions of
protein are growth; tissue repair, and muscle function and a spare source of energy when
carbohydrates are lacking in the diet 107. The current Dietary Reference Intake (DRI) is 0.8mg/kg
body weight 108. Protein is involved in bone metabolism, in the formation of the organic bone
matrix as collagen, in mineralization, and in calcium intake and metabolism 109. Past studies
report that diets high in protein increased urinary calcium loss, but it is unknown whether the
calcium excreted is purely from bone or from increased calcium absorption 110. There are
mechanisms that explain the possible deleterious effects of foods rich in animal protein.
Considering that the extracellular fluid pH is tightly controlled between 7.35 and 7.45 111, hepatic
oxidation of sulfur-containing amino acids (e.g. methionine and cysteine) to sulphuric acid and
ammonium ions causes a reduction in blood pH 107. Also, consumption of protein from meat,
dairy, and legumes has potential to cause renal acid loads resulting in diet-induced, low grade
metabolic acidosis 112. Both processes induce bone loss due to the key role played by bone
minerals in buffering the net acid load of the diet 107. A diet low in protein however, is associated
with reduced intestinal calcium absorption, which results in increased serum PTH, a situation
that leads to bone resorption 110. Dietary alkali load is achieved through consumption of
vegetables and fruits since potassium, sodium; calcium and magnesium generate bicarbonates or
citrate salts which lower extracellular pH 112, 113. However, protein intake requires careful
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balance due to its importance in other body processes including growth through regulation of
insulin-like growth factor (IGF), a recognized mediator of anabolic processes 107. Studies on
effects protein on bone are inconsistent, although beneficial effects have been reported in high
protein intake in the setting of adequate calcium intake 107.

Calcium
Calcium is an essential skeletal component that plays a critical role in many other body
functions. Calcium is plays a key role in blood coagulation, enzyme activity, muscle contraction,
membrane permeability, and hormones secretion 114. A constant concentration of calcium is
required in extracellular fluids to maintain health in humans. Blood calcium homeostasis is
maintained through the endocrine system mainly by regulation of vitamin D, parathyroid
hormone and calcitonin 114. As mentioned earlier, calcium is stored in the bone and when dietary
calcium is inadequate or its absorption impaired, the body withdraws calcium from bone, hence
loss of bone mineral density. There is clear evidence that an increased level of blood calcium
causes low levels of PTH and vice versa 114. Moreover, high blood levels of phosphorous inhibit
the formation of 1, 25 (OH) 2D resulting in low blood calcium and PTH stimulation 114. Calcium
supplementation is reported to be beneficial to postmenopausal women by increasing BMD,
because calcium deficiency causes an increase in PTH levels and PTH action aggravates bone
loss 115. Calcium can be intravenously infused to bring PTH levels to normal 115.

Vitamin D
Vitamin D is a fat soluble prohormone that is obtained from sun exposure, food, and
supplements in a biologically inert form. Vitamin D must undergo two hydroxylation reactions to
be activated in the body. The two inert forms of vitamin D are ergocalciferol or vitamin D2 and
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cholecalcificerol or vitamin D3 which must be converted to the active form, 1,25 (OH) 2D 5. It is
believed that the body stores of vitamin D are best reflected in the serum levels of their
precursors D2 and D3 (25-OH-vitamin D). Several major mechanisms by which vitamin D affects
bone have been identified. First, the active form of vitamin D works together with PTH and
calcitonin to regulate calcium homeostasis. These hormones regulate calcium homeostasis by
increasing and decreasing calcium absorption in the gut and modulating bone remodeling and
growth 5. Secondly, vitamin D reduces fracture risk by improving muscle function 115.
Furthermore, in humans, decreased levels of 25-OH-vitamin D, below 30ng/ml (80 nM) is
associated with elevated levels of PTH 55 resulting in bone turnover and ultimately bone loss.
Vitamin D has also been reported to stimulate production of OPG in human osteoblast lineage
cells which in turn suppresses osteoclastogenesis 116.

Micronutrients
Micronutrients, magnesium (Mg), fluoride (F), and Vitamin K are considered vital in
bone health. Fluoride is mainly found in calcified bone tissue and plays key role in dental health
117

. Magnesium deficiency is a recognized risk factor for osteoporosis 118 possibly because

approximately two thirds of the mg found in the body is stored in the bone and is an essential
cofactor for over 300 enzymes 118.
Vitamins are essential factors for metabolism, growth, reproduction, and immunity 119.
Vitamins, A, K, E, and C have shown bone protective effects in epidemiological studies 77. Some
vitamins are vital in the development and maintenance of bone health. Vitamin A for instance is
important for bone formation, but excess intake may lead to toxicity associated with bone loss
and a higher risk for hip fracture 120.
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Recent work has focused on the role of vitamin K in bone health since its role in blood
coagulation is fairly well understood 121. Evidence suggests that vitamin K is essential for the
post-translational conversion of glutamyl residues to carboxyglutamyl (Gla) residues in vitamin
K-dependent proteins prothrombin and osteocalcin 121. Furthermore, vitamin K is an important
factor in the modulation of osteoblastogenesis and osteoclastogenesis in bone marrow cells via
the RANKL pathway 32.
Vitamin E, contained in small amounts in most fruits and some vegetables, is a strong
antioxidant that scavenges reactive oxygen species protecting cells from oxidative damage.
Vitamin E supplementation is associated with maintaining BMD 122. Epidemiological studies
propose that low dietary intake of vitamins E and C is linked to increased hip fracture in smokers
123

.
Vitamin C, also known as ascorbic acid, is found in most fruits and vegetables. Vitamin

C is a key antioxidant vitamin recognized as an elemental component in the formation and
maturation of stable collagen in connective tissue 77. It is also required in hydroxylation of lysine
and proline necessary for collagen formation. Overt vitamin C deficiency is characterized by
non-organized and thinner growth plate, thinner trabecular network, very low collagen synthesis,
and decreased differentiation of osteoblasts from mesenchymal cells77. Studies have shown that
through vitamin C, TGFβ may act to stimulate osteoblast differentiation resulting in increased
bone formation 124. Low vitamin C intake in growing guinea pigs results in higher than normal
bone turnover 125. Several epidemiological studies have found an association between dietary
vitamin C intake and BMD in postmenopausal women 126.
Current evidence suggests that antioxidants both dietary and endogenous and especially
vitamin C plasma concentrations are reduced in elderly osteoporotic women 123. In an
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observational study of 533 non-smokers, randomly selected postmenopausal women, Pasco and
others 123 studied the associations among the use of antioxidant supplements, vitamins C and E,
serum levels of biochemical markers of bone turnover CTX-1 and BSAP, and whole body BMD.
This study found that only 22 participants were users of vitamin C and E, and duration of
antioxidant supplement use was negatively associated with age-adjusted and weight-adjusted
serum CTX-1. The results further showed that mean CTX-1 levels were 0.022 units lower for
each year of exposure and differences were not significant for adjusted serum BSAP or whole
body BMD 123. Dietary supplementation with antioxidant vitamin E or C suppresses bone
resorption in nonsmoking postmenopausal women 123.
FRUITS AND HEALTH
It is widely accepted that a diet high in plant-based foods decreases the risk for many
degenerative diseases 127. Consumption of fruits and vegetables has been associated with reduced
incidence of chronic inflammatory conditions including various cancers 128, 129, cardiovascular
disease, 130,131, and osteoporosis 132.Current efforts in human health are focused on preventing
diseases that may progress due to oxidative stress. Oxidative stress leads to cell and tissue
damage and is the etiology of many chronic diseases including cardiovascular conditions and
osteoporosis 133. There is growing evidence that dietary antioxidants from fruits and vegetables
reinforce the endogenous antioxidant defense systems present in the body and prevent chronic
diseases 127.
Fruits are a source of bioactive components including, minerals, fiber, vitamins and
phytochemicals 134. Vitamins found in fruits include, C, A, E, K and B1, B2, B6, niacin, folate,
and pantothenic acid 134. Minerals contained in fruits are essential cofactors in formation of many
enzymatic processes and metabolic processes hence adequate amounts prevent chronic
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conditions 134. Most fruits contain important bone forming minerals, potassium, calcium,
phosphorus, magnesium and sodium 135. Other important minerals found in varying amounts in
fruits include: selenium, manganese, copper, and zinc 134. Soluble and insoluble fibers found in
fruits slow down digestion hence increasing absorption of nutrients. For example, Ohta and
others noted increased absorption of magnesium and calcium administered together with dietary
fructooligosaccharides 136
Fruits also contain phenolic compounds with superoxide scavenging capacities 127.
Phenolic compounds function as antioxidants by easily donating hydrogen atoms from their
aromatic hydroxyl groups and by supporting unpaired electrons 137. Phenolic compounds
classified as antioxidants must meet two basic conditions when present at low concentrations
relative to the substrate: i) delay, retard, or prevent oxidation and ii) the radical formed must be
stable 138.
Phenolic compounds account for 80% of total antioxidant capacity in most fruits and
vegetables 139. The antioxidant capacities i.e. oxygen radical absorbance capacity (ORAC), of
certain phenolic compounds including flavonoids may be stronger than vitamin E and C based on
molar concentrations 139. Using eight healthy elderly women, Cao et al 119 investigated the effects
of consuming either 240g of strawberries, 294g of spinach, 300mls of red wine, or 1250mg of
vitamin C on serum antioxidant capacity. The study confirmed increased serum antioxidant
capacity from all four foods 119.
EFFECTS OF PHENOLIC COMPOUNDS PRESENT IN BLUEBERRY AND
BLACKBERRY ON HEALTH
The major groups of phenolic compounds present in berries are reported to be flavonoids,
flavonols, flavanols, ellagitannins, gallotannins, proanthocyanidins, and phenolic acids 140.
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Flavonoids include one of the largest and most important groups of the phenolic compounds, the
anthocyanins, which are prevalent in berries reaching 10g/kg in some varieties. In the United
States the most current estimation of anthocyanin intake is 12mg/day 141. Blueberries contain
mainly the flavonoids: anthocyanins, catechin, epicatechin, quercetin, kaempferol, myrecetin,
and phenolic acids (e.g., gallic acid, p-hydroxybenzoic acid, chlorogenic, p-coumaric, caffeic,
ferulic, and elagic acids) 142, 143. Blackberries on the other hand contain primarily anthocyanins,
flavonols, and hydrolysable tannins, chiefly ellagitannins 144. Anthocyanins display biological
activities including antioxidant, anti-inflammatory, antimicrobial and anti-carcinogenic activities
145

. These reports are especially useful in the prevention of obesity-induced inflammation which

is a major risk for cardiovascular diseases, type II diabetes, and certain types of cancer 145.
Anthocyanins are reported to improve vision and induce apoptosis of cancer cells 146.
Anthocyanins have also demonstrated positive effects on blood vessels and platelets that may
reduce the risk of coronary heart disease 146. For example, antioxidant activity of anthocyanins
from blackberries, red raspberries, sweet cherries, blueberries and strawberries inhibited human
LDL oxidation 144. Animal studies show that a type of anthocyanins, cyanidin-3-glucosides
improved hyperlipidemia and hyperglycemia in mice fed a high-fat diet 145.
Anthocyanins elicit anti-inflammatory properties by suppressing the production of proinflammatory mediators such as nitric oxide and prostaglandin E2 through nuclear factor- kappa
B inactivation in lipopolysaccharide-stimulated macrophages 145. Recently blueberry and
cranberry anthocyanins and hydroxycinnamic acids demonstrated anti-inflammatory properties
against H2O2 and TNF-α induced damage to human microvascular endothelial cells 147.
Blueberry anthocyanins also inhibited inflammation of neural cells 148 and mitigated the effects
of age related neural behavior decrements 149. Joseph and colleagues reported reversal of age
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related dysfunction using blueberry extract. Eight weeks on 1.86% blueberry diet, forty 19month-old adult male rats had improved motor performance on two motor tests that rely on
balance and coordination 149.
Procyanidins have potential health benefits and are reported to reduce the production of a
vasoconstrictive peptide endothelin-1 produced by endothelial cells and linked with chronic
inflammation of the arterial wall 150. Moreover, procyanidins known as A-type derived from
cranberries are known to be protective against urinary tract bacterial infections 151, cancer, and
vascular diseases 152. Bioactive berry phenolics are exploited in today’s market as food
supplements.
BLACKBERRIES AND BLUEBERRIES AND BONE HEALTH
Animal studies have demonstrated that phenolic compounds from berries scavenge ROS
formed by phagocytes (i.e. monocytes, macrophages and neutrophils) 38 resulting in bone
resorption 153. Polyphenols such as chlorogenic acid, caffeic acid, and rutin in dried plum have
prevented bone loss in animal models by reducing oxidative stress biomarkers 154. Resveratrol
the major phenolic compound in grapes has potential bone protective properties as demonstrated
by its ability to increase intracellular bone formation markers in experimental studies 155. Dried
plum and blueberries have some structurally similar phenolic and flavonoids compounds 156.
Recently blueberries have shown bone protective effects in ovariectomized (OVX) rat model of
postmenopausal osteoporosis. Feeding 5% blueberries (w/w) down regulated mRNA levels of
three bone matrix proteins: alkaline phosphatase (ALP), tartrate-resistant acid phosphatase
(TRAP), and collagen type 1 (COL) and significantly improved total bone mineral density 157.
Similarly, supplementation with blackberries at the level of 5% (w/w) protected bone mineral
density at fourth lumbar vertebra, right tibia, and left femur compared to controls in an
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ovariectomized rat model of postmenopausal osteoporosis 158 Although whole berries were
administered in the blueberry and black berry animal studies, phenolic compounds are thought to
be the major bioactive compounds responsible for bone health effects. The mechanism is still
unclear although it is reasonable to speculate that the compounds work by lowering oxidative
stress.
METABOLISM AND BIOAVAILABILITY OF ANTHOCYANINS
Although studies have revealed the human health benefits of anthocyanins, low
bioavailability has been suggested by the low concentration observed in plasma and urine after
ingestion of anthocyanins 159. Anthocyanins have been detected in human plasma in glycosylated
form by HPLC analysis 160. After 1.5g of anthocyanin intake given as an elderberry extract, Cao
and Prior 161 reported a maximal plasma anthocyanin concentration of 100μg/L after 30mins in a
human study. The anthocyanins were detected in their glycosidic forms 161.
Jian and colleagues 159 evaluated the impact of chemical structure of anthocyanins on
absorption and metabolism. Anthocyanin-rich extracts fed to rats for 3 months demonstrated that
anthocyanin diglucosides are better absorbed than their corresponding monoglucosides 159. The
study also showed that intact acylated anthocyanins are absorbed into plasma and excreted
through urine 159.
Matsumoto and others 162 fed a single dose of 3.57mg cyanidin-3-glycoside per kg body
weight to subjects and detected within 2 hours in plasma (0.120 nM) and urine samples (0.11%
of total ingested) 162. The anthocyanins in this study were from blackcurrant concentrate.
Investigating the bioavailability of anthocyanins from red wine, Lapidot and others traced
anthocyanins in human urine after consumption of 300mL of red wine containing approximately
218mg of anthocyanins. An estimated 1.5 - 5.1% of anthocyanins were recovered in urine 12
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hours after consumption and highest anthocyanin levels were reached within 6 hours after
consumption 163. Consumption of 1.2g anthocyanins from freeze-dried wild blueberry powder
led to identification of 11 different anthocyanins in serum 160. Maximal serum concentration
reached 4 hours later revealed the most abundant compound, cyaniding-3-glucoside ranged from
5.43-16.9ng/mL. Others identified include malvidin 3-galactoside, malvin-3-glucoside and
delphinidin-3-glucoside accounting for 27, 20 and 10 % of the total respectively 160.
A study by Mazza et al., compared serum antioxidant status of subjects after consumption
of blueberry powder plus a high fat meal to serum antioxidant status after a high fat meal without
blueberry powder 160. Subjects consumed a McDonald’s meal containing 853 calories, (46.7g of
fat-15.5g saturated fat) for the study 160. Blueberry consumption was associated with a significant
increase in serum lipid-soluble antioxidant status and prevented a decrease in serum antioxidant
capacity postprandial 160. Unlike other flavonols, such as quercetin glycosides, the bioavailability
of anthocyanins has been found to be consistently low across all studies. The amount appearing
in urine is often 0.1% of ingested dose 141. Low bioavailability of anthocyanins from red grape
juice, elderberry extract, boysenberry concentrate, and blackcurrant has been confirmed 141. The
highest anthocyanin recovery reported to date is a urinal excretion of 1.80% after consumption of
200g of strawberry yielding 179 μM of pelargonidin-3-glucoside 164.
Therefore, current evidence suggests that anthocyanins are absorbed rapidly and reach
maximal plasma concentration 15-60 minutes after consumption, and they are excreted 6-8 hours
later 141. The quick appearance in the circulatory system has led to the interpretation that
anthocyanins are absorbed in the stomach 141. Although gastric absorption of anthocyanins is
proven 165, evidence also suggests that absorption of cyanidin-3-glucoside may occur in the
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jejuna and duodenal tissue 166. There is also evidence that intact anthocyanin glycosides appear
to be absorbed, distributed, and then excreted in urine 141.
Anthocyanins may accumulate in tissue, and this may explain the apparent contradiction
of observed benefits and low plasma availability of anthocyanins 159. Gut microflora also play a
role involved in anthocyanin bioabsorption. For example, anthocyanin glycosides are degraded
by colonic bacteria into aglycones and smaller phenolic compounds 167. Aura et al used cyanidin3-glucoside and rutinoside as inoculums in human fecal microbiota and reported that through
deconjugating enzymes, rutinoside is metabolized into cyanidin-3- glycoside. Additionally, gut
microflora were found to deglycosylate anthocyanins and produce protocatechuic acid as the
major metabolite 167. At present, it is unclear how anthocyanins and their metabolites enter
circulation, are distributed to tissues in vivo and exert beneficial health effects 141. However, cell
culture studies have demonstrated that anthocyanins can penetrate mammalian cell walls. These
experiments show their potential bioactivity such as protection against oxidative stress, induction
of apoptosis, and changes in inflammatory response in vitro 141, 168.
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III.

THE BLACKBERRY FRUIT: A REVIEW ON ITS COMPOSITION AND
CHEMISTRY, METABOLISM AND BIOAVAILABILITY, AND HEALTH
BENEFITS

ABSTRACT
Blackberry (Rubus sp.) fruit contains high levels of anthocyanins and other phenolic compounds,
mainly flavonols and ellagitannins, which contribute to its high antioxidant capacity and other
biological activities. Blackberry phenolic composition and concentrations are known to be
influenced by genetics, growing conditions, and maturation. Despite our knowledge of their
chemistry, research specific to blackberry phenolic compounds’ health benefits, metabolism,
bioavailability, and mechanism by which they confer health benefits is scarce. Blackberry
phenolic compounds have protective effects on age-related neurodegenerative diseases, and bone
loss in vivo, and can inhibit LDL and liposomal oxidation in vitro. Blackberry extracts have also
exerted anti-mutagenic effects in vitro and in vivo by modifying cell signaling pathways and
suppressing tumor promotion factors. However, the anti-obesity, anti-diabetic, antimicrobial, and
anti-inflammatory properties of blackberry phenolic compounds need investigation. Similarly,
studies that elucidate the in vivo physiologically effective concentrations of blackberry phenolic
compounds are necessary.
KEYWORDS: blackberry, anthocyanins, bioavailability, flavonoids, health benefits.
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INTRODUCTION
Worldwide commercial production of blackberry (Rubus sp.) is estimated to be
approximately 154,578 tons annually (1). North America, Europe, Asia, South America, Oceania
Central America and Africa [in descending order of tons cultivated] are the main regions for
blackberry production (2). Wild blackberries are also cultivated in considerable amounts, and in
some regions may negatively affect the net sales of commercially cultivated fruit (2).
The “berry” weighs from 3-12 g depending on variety, and is best described as an
aggregate fruit made up of several drupelets, each containing a seed (1). Blackberries are mostly
consumed fresh but can be processed and sold as individually quick frozen packs, bulk frozen,
seedless or seed puree, freeze-dried, or as juice or concentrate (1). In industry, blackberries are
used for the production of dietary supplements, ice-cream, jam, marmalade and other
confectionaries (3).
Blackberry is a fruit of interest because of its high content of anthocyanins and
ellagitannins (ETs) as well as other phenolic compounds that contribute to its high antioxidant
capacity (4). Several studies document the high antioxidant activity of blackberries based on
their oxygen radical absorbance capacity (ORAC) compared to other fruits (4). In fact,
blackberries’ medicinal qualities have been known since the 16th century in Europe where they
were used to treat infections of the mouth and eyes (5).
Epidemiological and clinical studies (6-10) suggest that consumption of anthocyanins and
other flavonoids found in most fruits and vegetables may decrease the risk of obesity, coronary
heart disease, degenerative conditions, and various types of cancer. These health benefits and
mechanisms by which anthocyanins confer them have been explored in vitro (7, 11, 12) and in
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animal models (13-16). This review presents current knowledge on the chemistry, composition,
metabolism and bioavailability, and health benefits of blackberries.
NUTRIENT COMPOSITION
Blackberry chemical composition varies based on variety, growing conditions, stage of
ripeness, and harvest and storage conditions (17). In addition to valuable polyphenolic
compounds, blackberries contain carbohydrates, and several essential vitamins and minerals
(Table 1) (18).
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The principle sugars in blackberries are glucose, fructose and sucrose and their ratios
differ among cultivars (19). The principle sugars are glucose and fructose in the ratio of
approximately 3.24 - 2.88g/100g FW and 0.81-1.17 g/100 g FW glucose to fructose. Sucrose
content is estimated to be 0.24 g/100 g FW (19). Levels of glucose, fructose, total sugars and
total soluble solids increase markedly as the fruit ripens from light red to dark bluish purple
stages (20).
Blackberries contain malic acid as the primary organic acid although different acids
including ascorbic acid have been detected in the fruit (3). Fan-Chiang (19) reported the
following averages of nonvolatile organic acids from 52 samples of blackberry: 280 mg/100g
FW malic acid; 293 mg/100g FW lactoisocitric acid; 599 mg/100g FW isocitric acid; and 572
mg/100g FW citric acid. Furthermore, trace amounts of shikimic, fumaric and succinic acids
were identified (19). These organic acids in blackberries are important for stabilizing
anthocyanins and ascorbic acid, and extending the shelf-life of fresh and processed berries (17).
The balance in proportion of organic and phenolic acids in berries is evaluated for overall index
of fruit quality, whereas low pH is considered an indicator of poor quality (17). Another
important quality index for berries is the ratio of total soluble solids to total titratable acidity.
This ratio
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Table 3.1. Chemical composition of blackberries From the U.S. Department of
Agriculture Nutrient Database (18)

Proximates and
carbohydrates

vitamin content

mineral content

total ascorbic acid
water (g)

88.20

(mg)

21.00

calcium (mg)

29.00

energy (Kcal)

43.00

thiamin (mg)

0.02

iron ( mg)

0.62

protein (g)

1.39

riboflavin (mg)

0.03

magnesium (mg)

20.00

total lipids (g)

0.49

niacin ( mg)

0.65

phosphorus (mg)

22.00

ash (g)

0.37

pantothenic acid (mg)

0.28

potassium (mg)

162.00

carbohydrate (g)

9.61

vitamin B6 (mg)

0.03

sodium (mg)

1.00

total fiber (g)

5.30

total folate (µg)

25.00

zinc (mg)

0.53

total sugars (g)

4.88

vitamin B12 (µg)

ND

copper (mg)

0.17

sucrose (g)

0.07

vitamin A (IU)

214.00

manganese (mg)

0.65

glucose (g)

2.31

α-tocopherol (mg)

1.17

selenium (mg)

0.40

fructose (g)

2.40

β- tocopherol (mg)

0.04

maltose (g)

0.07

γ-tocopherol (mg)

1.34

galactose (g)

0.03

Δ-tocopherol (mg)

0.90

starch (g)

ND

vitamin K (µg)

19.80

ND, not detected
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Table 3.2. Total Phenolics and Total Anthocyanin Values of Blackberries across Studies

a

total phenolics
(mg GAE/100)

total anthocyanins
(mg/100 g FW)

number of cultivars

source

g NA
FW)

114-242 b

6

(4)

292-446

NA

6

(23)

248-633

NA

12

(27)

NA

70-201b

51

(28)

NA

58-219a

12

(29)

822-844

154-225 b

2

(30)

NA

80-230 b

27

(31)

418-555

111-123 b

2

(32)

NA

133-172 b

3

(33)

193-352

67-127 b

7

(34)

495-583

95-155 b

2

(35)

221 -342

38-72 b

5

(36)

114-178

31-118 b

4

(37)

NA

83-326 b

16

(38)

682-1056

131-256 b

11

(39)

Calculated as cyanidin 3-galactoside equivalents; bCalculated as cyanidin 3-glucoside

equivalents FW: fresh weight; NA not available
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increases in blackberries as the fruit ripens from purple to dark bluish purple stages, reflecting
the large increase in sugars and decline in organic acids (20).
Blackberries contain cell wall hydrolase and oxidase enzymes, such as polyphenol
oxidase and peroxidase, which contribute to deterioration of quality in fresh, damaged, or pureed
fruit (17). Enzyme activity results in loss of texture, brown pigment formation, and destruction of
phytochemicals that affects acceptability of particularly fresh fruit (17). Refrigeration, reduced
oxygen, addition of enzyme inhibitors, pH modification and addition of reducing agents to
control secondary oxidation are some of the techniques currently used to control enzyme activity
(17).
PHENOLIC COMPOSITION
Blackberries are a rich source of polyphenolics including, anthocyanins (21), ETs (22),
flavonols (23), flavan-3-ols, and procyanidins (24). The berries also contain appreciable levels of
phenolic acids (25) and low levels of lignans (26). Total phenolics in blackberries have been
shown to range from 114 to 1056 mg/100 g fresh weight (FW) (Table 2).Besides genetics, fruit
maturity can influence levels of total phenolics in blackberries. For example, analysis of three
blackberry cultivars namely ‘Chester Thornless’, ‘Hull Thornless’, and ‘Triple Crown’ berries
demonstrated that total phenolic content significantly decreases as the fruit matures from the
green to ripe stages (33). However, in another study involving tropical highland blackberries
levels of total phenolics fluctuated as the fruit ripened from light red (580 mg/100g FW) to
purple (460 mg/100g FW) to dark bluish purple (520 mg/100g FW) stages (20).
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Anthocyanins
Anthocyanins are the phenolic compounds responsible for the red to purple to black
pigments of fruits and vegetables (28) and are recognized for their potential health benefits (7).
Anthocyanins are flavonoids by classification and are predominantly found in berries and red
grapes (4). They are anthocyandinins glycosylated with one or more sugar moieties at the C3
position of the flavan structure (25). Approximately 94% of blackberry anthocyanins occur in
nonacylated form and 90% of these exist as monoglycosides while 10% are found as
diglycosides (21) (Table 3).
Blackberry anthocyanins are mainly cyanidin derivatives with glucose, rutinose, xylose
and arabinose moieties attached at C3 (21, 25) (Figure 1). Blackberry anthocyanins identified
include: cyanidin 3-glucoside, cyanidin 3-galactoside, cyanidin 3-xyloside, cyanidin 3-dioxalylglucoside, cyanidin 3-rutinoside, cyanidin 3-sophoroside and cyanidin 3-glucosylrutinoside
cyanidin 3-arabinoside, malvidin 3-arabinoside, perlargonidin 3-glucoside, cyanidin 3-(3malonyl) glucoside and cyanidin 3-(6-malonyl) glucoside (40, 41). Cyanidin 3-dioxaloylglucoside, a zwitterionic anthocyanin is unique to blackberries (42). Studies show that
anthocyanin content of blackberry varies due to differences in variety, environmental conditions,
and cultivation site, degree of ripeness and processing (43). Cho et al. reported total anthocyanin
content of 6 blackberry genotypes to range from 114.4 mg/100g fresh weight (FW) to 241.5
mg/100g FW (4). In a similar study, Fan-Chiang and Wrolstad found monomeric anthocyanin
content in 51 cultivars ranged from 70 to 201 mg/100 g FW and, the cyanidin derivatives
dominated in all samples with a mean peak area of 83% (28).
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Table 3.3 A Summary of Anthocyanins, Flavonols, and ETs Identified in Blackberries
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anthocyanins

flavonols

ellagitannins

cyanidin 3-galactoside

quercetin 3-galactoside

sanguiin H-6

cyanidin 3-glucoside

quercetin 3-glucoside

lambertianin C

cyanidin 3-arabinoside,

quercetin 3-rutinoside

pedunculagin

cyanidin 3-xyloside

quercetin 3-xylosylglucuronide

lambertianin D

alvidin 3-arabinoside

quercetin 3-glucosylpentoside

galloyl-bis-HHDP glucose

perlargonidin 3-glucoside

kaempferol 3-glucuronide

sanguiin H-10 isomer (2)

cyanidin 3-rutinoside

kaempferol 3-glucoside

sanguiin H-6 minus gallic acid moiety

cyanidin 3-sophoroside

kaempferol 3-galactoside

lambertianin C minus ellagic acid moiety

cyanidin 3-glucosylrutinoside

kaempferol 3-xylosylglucuronide

galloyl-HHDP
glucose
(4)

cyanidin 3-(3-malonyl) glucoside

quercetin 3-glucuronide

sanguiin H-2

cyanidin 3-(6-malonyl) glucoside

quercetin 3-О-[6-(3-hydroxy-3-methyl-

sanguiin H-6 plus gallic acid moiety

myricetin
glutaroyl)-B-D-galactoside

castalagin/vescalagin

quercetin 3-methoxyhexoside

ellagic acid

quercetin 3-oxalylpentoside

methyl ellagic acid pentose conjugate (2)

Compiled from the following references (25, 32, 52).

Anthocyanidin
Cyanidin
Pelargonidin
Malvidin

R1
OH
H
OCH3

R2
OH
OH
OH

R3
H
H
OCH3

Figure 3.1. Chemical structures of blackberry anthocyanidins
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Flavonol
Quercetin
Kaempferol
Myricetin

R1
OH:
H
OH:

R2
H
H
OH

Figure 3.2. Chemical structures of blackberry flavonol
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Moreover, cyanidin derivatives may vary in blackberries due to genetic differences (28). This
concept was demonstrated by Fan-Chiang et al. (28) using 51 samples of blackberries as follows:
cyanidin 3-glucoside 44% to 95%; cyanidin 3-rutinoside trace amounts to 53%; cyanidin 3xyloside, undetectable amounts to 11%; cyanidin 3-(malonyl) glucoside, trace amounts to 5%,
and for cyanidin 3-dioxaloylglucoside, undetectable amounts to 15% (25, 28).
Similarly, six blackberry genotypes analyzed by Cho et al. (4) demonstrated that
distribution of cyanidin aglycones in each variety ranged from 75% to 84% for cyanidin 3glucoside, 1% to 12% for cyanidin 3-rutinoside, 4% to 8% for cyanidin 3-dioxaloyglucoside, 3%
to 8% for cyanidin 3-dioloylglucoside and 2% to 3% for cyanidin 3-(malonyl) glucoside (4, 25).
Reyes-Carmona et al. (44) observed similar differences when comparing three cultivars: Marion,
Evergreen and Comanche berries. Unlike Marion and Evergreen, Comache contained higher
amounts of cyanidin 3-rutinoside than cyanidin 3-glucosides; however, Comache’s content of
cyanidin 3-glucoside was still higher than Evergreen and Marion berries. Furthermore, malvidin
3-glucoside was identified in Marion and Evergreen, but not in Comanche berries (44).
Anthocyanins are synthesized during blackberry ripening resulting in the development of a dark
bluish purple color. Consistent with visual color change total anthocyanins increase markedly as
the fruit ripens from pink/light red to dark bluish purple stages (20, 33).
Flavonols
The structure of flavonols entails a double bond at C2 and C3, a hydroxyl group at C3
and a ketone group at C4 of the C ring of the flavan nucleus (25) (Figure 2). Quercetin, myricetin
and kaempferol are the most commonly identified flavonols in berries; their main difference is
the number and position of OH groups at C3 and C5 (45). The sugars commonly attached at the
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C3 position are glucose and galactose, but arabinose, rhamnose, rutinose and xylose may also be
found (45).
Blackberries contain appreciable amounts of flavonols found exclusively in the fleshy
part of the drupelet (30) and occur mostly in glycosylated form (23). Reported values for total
flavonols calculated as rutin equivalents are as follows: 12 to18 mg/100 g FW, 4 to 9 mg/100
FW, not detectable to 10 mg/100 g FW, 10 to 16 mg/100 FW, 10 to 16 mg/100 FW and 11-30
mg/100 FW (4, 23, 30, 32, 35, 46).
Blackberries have a complex flavonol profile due to the occurrence of nine quercetin and
three kaempferol derivatives as well as two acylated quercetin-derived compounds (Table 3). In
addition, quercetin 3-xylosylglucuronide, a different flavonol is reported in some blackberry
varieties (43). According to Cho et al. (23) quercetin 3-galactoside and quercetin 3-glucoside are
the main flavonols in five blackberry genotypes, although a few varieties contain high levels of
the acylated form of quercetin 3-[6-(3-hydroxy-3-methylglutaroyl)]-β-galactoside (23). The
occurrence of kaempferol and myricetin is not consistent for all blackberry genotypes probably
due to genetic differences (4, 39, 47). Bilk and Sapers (48), reported that ripe fruits of thorn
blackberry (Rubus spp.) contain 0.5 to 3.5 mg/100g FW and 0.1 to 0.3 mg/100g FW of quercetin
and kaempferol respectively (48), while Sellappan and colleagues (32) reported 9.9 mg/100g of
myricetin in Georgia-grown blackberries. Levels of total flavonols in tropical highland
blackberries are reported to decline as the fruit ripens from light red (30 mg/100g FW) to dark
bluish purple (14 mg/100g FW) stages (20).
Phenolic acids
Phenolic acids in blackberry fruit range from 7 to 64 mg/100 g FW and are mainly
hydroxybenzoic acid and hydroxycinnamic acids. These acids occur in conjugated forms of
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esters and glycosides, but rarely as free acids (25). Esters make up 53.1% of total phenolic acids
while glycosides and free acids account for 43.6% and 3.3% respectively (49). Blackberry
hydroxybenzoic acids include: p-hydrobenzoic, protocatechuic, gallic, vanillic, salicylic and
gentisic acid. Glycosidic and ester forms of salicylic acid are the most common (49).
Caffeic, m-coumaric, p-coumaric and ferulic acid are hydoxycinnamic acids found in
blackberries in free, ester and glycosidic forms. The ester forms of m-coumaric, 3,4dimethoxycinnamic and hydroxycaffeic acids are predominant (49). Blackberry hydroxybenzoic
and hydroxycinnamic acid derivatives have been classified as follows: chlorogenic acid,
neochlorogenic acid, glucose esters of caffeic, p-coumaric, ferulic, and gallic acids, as well as
protocatechuic acids and the β-D-glucosides of p-coumaric and p-hydroxybenzoic acids (50)
Ellagic acid (EA) is a hydroxybenzoic acid, but most of EA found in blackberries is in
the form of ETs which is a different class of phenolics. Blackberry EA calculated as “ellagic acid
equivalents” following acid hydrolysis has been reported in several studies to range from: 2 to 4
mg/100 g FW (30), 2 to 34 mg/100 g FW (49), 12 to 18 mg/100 g FW (46), and 21 to 25 mg/100
g FW (37), 30 to 34 mg/100 g FW (32), and 59 to 90 mg/100 g FW (35). Ellagic acid derivatives
are reported to decline as blackberries ripen from light red (30 mg/100g FW) to dark bluish
purple (20 mg/100g FW) stages (20).
Tannins
Tannins are a group of polyphenolic compounds found in many berry fruits and include
oligomeric and polymeric constituents (41). Tannins are known to be anti-nutritional because the
tannins bind to –NH groups of peptides, precipitate them and prevent their hydrolysis in the
stomach (41). For example flavan-3-ols (catechins) and flavan-3, 4-diols (leucoanthocyanins)
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interact with proteins, starch and digestive enzymes, to form less-digestible complexes resulting
in reduced absorption of these nutrients (51).
Tannins are classified into two groups based on their structure: condensed tannins .i.e.
proanthocyanidins and hydrolyzable tannins i.e. ellagitannins (ETs) and gallotannins (41).
Proanthocyanidins are oligomers and polymers of flavonoids and in particular flavan-3-ols
whereas the hydrolyzable tannins are glycosylated gallic acids (41). Berry fruits contain two
major types of proanthocyanidins: procyanidins and propelargonidins. The procyanidins and
propelargonidins are composed exclusively of (epi) catechin and (epi) afzelechin units
respectively (25). Based on the hydroxylation pattern of A- and B-rings, proanthocyadinins (MW
2000-4000Da or more) are categorized into three groups: procyanidins, prodelphinidins and
propelargonidins (41). There are about 50 procyanidins identified from plants (41). Procyanidins
in blackberries have been found to be predominantly epicatechin units linked through C4→C8
bond, the so called “B-type” linkage, with an average degree of polymerization of 3.2 (24).
Blackberries contain monomers (7.3 mg/100g FW), dimers (6.7 mg/100g FW), trimers (3.6
mg/100g FW), tetramers to hexamers (7.3 mg/100g FW), heptamers to pentamers (4.2 mg/100g
FW), and low levels of polymers (1.5 mg/100g FW) resulting in a total procyanidin content of
27.0 mg/100g FW (24). Hydrolysable tannins, specifically ETs of varying molecular weight are
found in blackberries in appreciable amounts (25). Ellagitannin and EA derivatives are
identified using high performance liquid chromatography mass spectrometry (HPLC-MS), and
results are commonly reported as “ellagic acid equivalents” due to the diversity of ETs in berries,
and lack of ellagitannin standards (25).
Blackberry ET structures are complex, large, and diverse, which presents a challenge in
their characterization (52) (Table 3). The basic structure of ETs consists of a glucose core
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esterified with hexahydroxydiphenic acid (HHDP) (Figure 3). When hydrolyzed by either an
acid or a base, HHDP is changed to the dilactone form, EA (25). An ET bis-HHDP
glucopyranose is also known as pedunculagin, and the galloylated form, or galloylbis-HHDP
glucopyranose is also known as casuarictin or potentillin (52). Moreover these compounds can
be found as α-or β-glucopyranosides (53) with the HHDP units R or S configurations relative to
C4 and C1 of the glucose (54). ETs found in blackberry fruit and leaves are mostly polymerized
forms of the galloyl-bis-HHDP (52).
Blackberry seeds contain the highest amount of ETs and EA compared to other parts of
the fruit i.e. the torus, and flesh (30). In fact, 88% of the ETs and EA is found in the seeds
compared to only 12% in the pulp. EA derivatives in blackberries range from 1.2 to 3.0 mg/100 g
whereas ETs range from 51.1 to 68.2 mg/100 mg (46). The seeds of Marion and Evergreen
blackberry cultivars have higher ellagitannin values than most cultivars containing up to 3230
and 2120 mg/100 g seed of total ellagic acid, respectively (22).
Recently, blackberries were investigated by high-performance liquid chromatographyelectrospray ionization-mass spectrometry and matrix-assisted laser desorption/ionization-time
of-flight mass spectrometry (MALDI-TOF-MS) to identify the ETs (52). The following eleven
ETs were identified mainly in the seed and torus of the Apache cultivar of blackberries: isomeric
forms of pedunculagin, castalagin/vescalagin, galloyl-HHDP glucose, lambertianin C, and
lambertianin D, and galloyl-bis-HHDP glucose, and sanguiin H-6/lambertianin A, EA (52). This
study also proposed that blackberry fruit may contain sanguiin H-10 (52). In another recent
study, ETs and EA conjugates in six blackberry cultivars were identified and quantified using
ultra high pressure liquid chromatography-quadrapole-time of flight mass spectrometry (UPLCQ-TOF-MS) and HPLC-DAD analysis (55). In this study the authors isolated and purified the
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two major ETs found in blackberries, Lambertianin C and Sanguiin H-6 and used them as
calibration standards. Besides Lambertianin C and Sanguiin H-6, which account for 67% of the
total ETs, they identified twelve additional ETs, as well as EA and two EA conjugates. The
levels of total ETs in the six cultivars ranged from 84.7 to 130.4 mg/100g FW, while total EA
conjugates ranged from 12.8 to 27.4 mg/100g FW. The ETs, potentillin, pedunculagin and
casuaricitin have also been identified in leaves and shoots of blackberries (56). Notably, ET and
ellagic content of blackberries is affected by maturation. For instance, in the tropical highland
blackberry cultivar, Rubus adenotrichus known to have the highest amount of ETs in an edible
fruit when light red (380mg ellagic acid equiv/100g
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A

C

B

D
Figure 3.3. Structures of gallic acid (A), Ellagic acid (B) and galloyl-bis-HHDP glucose

(C), Sanguiin H-6/lambertianin A (D) Structures adapted from ref 52.
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E
Figure 3.3. continued Structure of lambertianin C (E), structure adapted from ref 52
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of fresh fruits), the two major ETs Lambertianin C and Sanguiin H-6 decline 33% from light red
to dark bluish purple stages (20).
OTHER PHYTOCHEMICALS
Lignans
Lignans are biphenolic compounds recognized as phytoestrogens and play an important
role in prevention of hormone-associated cancers such as breast cancer (57-59), and other
conditions including cardiovascular disease (60, 61) and osteoporosis (62). Blackberries are
unique as they contain both secoisolariciresinol (3.72 mg/100 DW) and matairesinol (<0.01
mg/100 g DW) (26). These lignans are known to be converted to mammalian lignans
enterolactone and enterodiol by gut microflora (63).
METABOLISM AND BIOAVAILABILITY
Although phytochemicals have been studied extensively, there is insufficient information
regarding changes in content and character of polyphenolic compounds once consumed (64). In
general, bioabsorption of anthocyanins, which are the most studied and abundant flavonoids,
occurs very quickly after consumption appearing in plasma 15-60 min postprandial and excretion
is complete within 6-8 h (65-73). Hollman et al. (74) noted that glycosylation of flavonols and
their derivatives influence their metabolism, absorption and bioavailability in vivo. Following
absorption, anthocyanins are metabolized differently based on their aglycones via methylation,
glucuronidation, and sulfoconjugation (69, 70, 75-77). This pathway uses conjugations with
glucuronic acid or with sulfate and is considered important in detoxication pathway of many
drugs and xenobiotic substances (67). These processes are catalyzed by UDP-glucuronosyl
transferase and sulfotransferase respectively, in the small intestine, liver and or kidney (67).
Some animal (78, 79) and human studies (73, 80) are consistent with these pathways since
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glucuronide forms of different subclasses of flavonoids have been found in plasma or urine (81,
82).
Anthocyanins are absorbed in intact glycoside forms from the digestive tract into the
blood circulation system in mammals (83). Although some argue that anthocyanins are too
hydrophilic to be absorbed into cells of animals and humans (84), there are studies (85, 86) that
support this pathway for small molecular compounds such as cyanidin-3-glucoside. Other
polyphenolic compounds such as free simple phenolic acids, aglycones, can also be metabolized
in the gut and absorbed by enterocytes (87-89). Anthocyanins have also been reported to be
substrates of bilitranslocase, which is a plasma membrane carrier involved in organic anion
uptake and mainly expressed at the sinusoidal domain of the liver plasma membrane and in
epithelial cells of the gastric mucosa (86). Using in situ exposure to tissue, investigators have
found that absorption occurs in the stomach, jejunum and duodenal tissue possibly through
interaction with bilitranslocase (65, 85, 90).
Anthocyanins are also thought to be metabolized via intestinal microflora through
cleavage of the C-ring to produce a range of phenolic acids which are easily absorbed (75).
Previously, scientists thought that the absorption of glycosides was not possible in mammals due
to the lack of suitable β-glycosidases (91), but light has been shed on the role of glycosidases
from gut microflora in the ileum that aid in metabolism and absorption of glycosides such as
quercetin glycosides (88, 92). However, this mechanism is unclear since the gut pH affects the
stability of individual flavonoids and especially anthocyanins, which actually results in increased
recovery of intact compounds in feces (68, 79, 93). Complex anthocyanins containing di- or
triglycosides are reported to remain in the gut longer than simple anthocyanins
(e.g.monoglycosides); and consequently plasma total antioxidant capacity and total anthocyanins
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remain high longer after feeding (68). It has been suggested that it is by this mechanism that
anthocyanins provide significant antioxidant protection in the environment of the gut epithelium
(68).
Studies on the metabolism of blackberry cyanidin glycosides in particular are limited. In
general, cyanidin glycosides are absorbed intact in the gut or conjugated with glucuronide or
methylated in the liver or gut, and either excreted into the bile directly or may enter blood
circulation and excreted in urine (67, 80, 94). The conjugated compounds identified so far
include, peonidin monoglucuronide, peonidin-3-glucuronide, and cyanidin 3-glucoside
monoglucuronide (67). Glucuronidation of cyanidin 3-glucoside has also been established in vivo
and in vitro (67, 81). It has been suggested that although all four free hydroxyl groups of
cyanidin have different glucuronidation capacities, glucuronidation of cyanidin-3-glucoside
occurs most readily at the 3-position (67, 81). Quercetin glycosides which are also abundant in
blackberries are converted to glucosides resulting in rapid absorption possibly via glucose
transporters in the gut (92, 95-97).
Systemic bioavailability of anthocyanins in general is very low across all studies, often
between 0.02% and 1.8% of the ingested amounts although as low as 0.004 to 0.11% of
administered dose has been reported (75). A human study by Felgines and others (69) fed 200 g
of blackberries containing 960 μmol of anthocyanins to five healthy volunteers and found that
only 0.16% of total amount of anthocyanins ingested were excreted in urine, mainly in the form
of methylated and glucuronidated conjugates (69). The study identified cyanidin 3-glucoside,
methylated glycosides, glucuronides of anthocyanidins and anthocyanins, and sulfoconjugate of
cyanidin, and anthocyanidins. Monoglucuronides of anthocyanidins accounted for > 60% of the
total anthocyanins in the urine (69). Findings on the metabolism and bioavailability of
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polyphenolic compounds may vary due to differences in animal models and experimental
designs. Additionally, these compounds have different chemical structures and solubility can
interact with macro and micronutrients, and they also vary in susceptibility to digestion,
conjugation, methylation, fermentation, and absorption in the gut (91).
Studies pertinent to the metabolism and bioavailability of blackberry ETs and EA are
lacking. However, this section will briefly highlight the metabolism and bioavailability of
various other ETs and EA found in literature and hypothesize that the pathways may be similar.
A study on punicalagin, an ET found in both blackberries and pomegranate was
detectable in human plasma and urine after consumption of 180 ml of pomegranate juice (98).
The juice contained 25 mg and 318 mg of EA and ETs, respectively. The highest concentration
of EA in human plasma 1hr postprandial was 31.9 ng/ml and EA was eliminated within 4 h (98).
The authors hypothesized that ETs and EA were metabolized by the colon microbiota hence the
appearance of free EA in human plasma (98). In rats, ETs are hydrolysable to EA by gut
microbiota in the small intestine and cecum (99). EA fed to rats was detected in the form of
urolithin A, also known as 3,8-dihydroxy-6H-dibenzo[b, d]pyran-6-one and an unidentified
metabolite in urine and feces. Investigators detected as much as 10% of given dose in this study
(100). Further work using germ free animals showed that these metabolites resulted from action
by gut microorganisms (100). EA can also be metabolized via conjugation possibly in the liver or
in the gut as evident by two conjugates of urolithin A found in rats after ingestion of EA (100). A
mice study using phenol EA (3H-EA) also detected free EA and conjugates in urine, bile and
blood and after gavage and 80% of fecal sample fraction was free EA (101). A study using
Iberian pigs, demonstrated that ETs release EA in vivo followed by a gradual metabolism of and
production of urolithin D, C, A and B in this order from the jejunum to the distal portion of the
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intestine (102). Furthermore, absorption of these metabolites was found to increase with their
increasing lipophilicity (102). Therefore, ETs and EA are metabolized by the gut microbiota of
different mammals (98, 102, 103) resulting in dibenzopyranones, urolithin A and its
monohydroxylated analog urolithin B, C, and D (104). It is thought that ETs are hydrolyzed to
EA due to the intestinal pH and or action by gut microflora, and EA is transformed to urolithins
A, B, C and D by gut microflora through lactone-ring cleavage via decarboxylation, and
dehydroxylation reactions (102). The Iberian pig study also confirmed enterohepatic circulation
activity as glucuronides and methyl glucuronides of EA and urolithin A, C, and D derivatives
were detected in bile and urolithins A, and B, and dimethyl-EA glucuronide were found in
peripheral plasma (102).
Because it takes 12-56 h to complete excretion of urolithins and their metabolites, their
distribution in tissues such as liver, lung kidney, heart, muscle and adipose tissue have been
investigated. No such metabolites were detected in these tissues in pigs (102), although traces of
punicalagin metabolites were reported in the kidney and liver of rats (103), and in colon,
intestinal, and prostate tissues of mice (105).
In summary, gut microbiota are responsible for hydrolysis of ETs to EA and subsequently
to glucuronides and methyl glucuronides of EA, and urolithins A, B, C, and D, and urolithin
derivatives. It has been suggested that differences exist in the metabolism of ETs and EA based
on food sources, and host colonic microﬂora composition that result in variation in the timing,
quantity and types of urolithins absorbed and excreted in urine (106). Therefore, metabolism and
bioavailability of particular blackberry ETs and EA require investigation as a step towards
exploring their health benefits.
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HEALTH BENEFITS
Anthocyanins are reported to exert anti- inflammatory, antiviral, antiproliferant and
anticarcinogenic properties (51). The consumption of anthocyanins in the U.S. is generally
higher than other flavonoids due to their widespread distribution and occurrence in fruits and
vegetables (65, 107), and is estimated to be between 82-215 mg/day. Presently, data on dietary
intake of blackberry ETs and EA are lacking. However as a reference, daily dietary intake of ETs
from berries in the Finnish and German populations are 12 and 5 mg/day, respectively (108,
109). Health benefits of particular blackberry ETs and EA have also not been explored, although
a recently published review of ETs and EA is detailed on the anti-inflammatory, antimicrobial,
prebiotic, antioxidant and estrogenic and/or anti-estrogenic of dietary ETs and EA (110).

Oxidative stress
Living organisms have a reduction-oxidation system that is necessary to maintain a
balance between free radicals generated and antioxidant system (75). The formation of large
amounts of free radicals may cause oxidative stress (OS) leading to many degenerative diseases
and aging (75, 111-113). Although some scientists argue that in many instances oxidative stress
is not the primary cause of disease and that the formation of radicals is secondary to tissue
damage by disease, (51) there is some evidence linking OS with several chronic diseases (114,
115).
Wada and Ou (35) ranked the antioxidant activity of blackberries third highest after
strawberry and black raspberry based on their oxygen radical absorbance capacity (ORAC) (35).
This can be attributed to the high amounts of acylated anthocyanins and cyanidin 3-glucoside in
blackberries. In fact, cyanidin-3-glucoside is ranked high in ORAC activity, and is reported to be
3.5 times stronger than Trolox (vitamin E analogue), while pelargonidin, also found in
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blackberries, was reported to have antioxidant activity equivalent to Trolox (107). Acylated
anthocyanins are highly correlated with antioxidant capacity in fruit (4). Cho et al. observed a
strong linear relationship between oxygen radical absorbance capacity (ORAC) values and total
acylated anthocyanins (rxy= 0.91) in blackberry extracts and this correlation was weaker for total
anthocyanin monoglucosides (rxy =0.69) (4). This correlation is consistent with bioavailability
studies that demonstrate structural differences in anthocyanins such as sugar
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Table 3.4. ORAC Values (µmol Trolox Equiv/g) of Blackberries a aFL represents ORAC
results using fluorescein probe while PE represents ORAC results using B-PE probe

fresh weight

dry weight

no. of

(µmol Trolox equiv/g)

(µmol Trolox equiv/g)

cultivars

source

63-83FL

6

(4)

49-76 FL

6

(23)

34-36 PE

2

(30)

27-71PE

27

(31)

3

(33)

20-25 PE

3

(33)

28 PE

2

(35)

11

(44)

38-76 PE

11

(39)

17-67FL

15

(117)

4

(118)

20-22FL

-

121-146FL

334-560 FL

43-62 FL
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moieties and acylated groups affect bioavailability, stability and other biological effects of
anthocyanins (21). It should be noted that biological activities of berry components may vary
with species and even cultivars (75).
Anthocyanins work by scavenging free radicals with 3, 4-dihydroxy substituent in the B
ring (75) being a key criterion for radical scavenging. They react readily with radicals such as
hydroxyl (∙OH), azide (N3∙) and peroxyl (ROO∙) to form stable flavonoid radicals (51), hence
reducing oxidative stress (116). Flavonoids however are slower at reacting with lipid peroxl
(LOO∙) radicals and superoxide (O2−) due to reduced availability of polar flavonoids for reaction
with the LOO∙ radicals (116). They also enhance fatty acid stability by reacting with αtocopherol radicals to form α-tocopherol (51, 116). Anthocyanins also function as antioxidants
by chelating metal ions at moderate pH levels with their ionized hydroxyl groups of the B ring
(75).
Several studies have examined the ORAC of blackberries and results are presented in
Table 4. When comparing ORAC results by different authors, it should be noted that the use of
fluorescein probe results in higher ORAC values, typically 1.5 to 3.5-fold compared to older
studies that used the B-PE probe (119).

Cardiovascular Disease
Elevated levels of low density lipoproteins in plasma are an independent risk factor for
cardiovascular disease (120). Berry phenolic compounds have shown protective effects against
cardiovascular disease by inhibiting in vitro and in vivo oxidation of LDL by quenching free
radicals through donation of hydrogen molecules (41). Berry phenolic compounds also protect
low density lipoproteins (LDL) from hydrogen peroxide-induced oxidative stress in human
endothelial cell in vitro (75).
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Blackberries phenolic compounds demonstrated strong inhibitory properties in vitro
using oxidation assays on human LDL and lecithin liposomes (121). High content of cyanidin
glycosides in blackberries are responsible for the high antioxidant activity and protection against
LDL oxidation while the hydroxycinnamic acids are most important in liposome oxidation
system (121). Anthocyanins, flavan-3-ols and hydroxycinnamic acids have been shown to have
inhibitory effects in liposomal oxidation (121). Furthermore, anthocyanins have exerted
protective effects in vitro on human primary endothelial cells by suppressing the secretion of
cytokine-induced chemokine monocyte chemotactic protein 1 (MCP-1) (72). MCP-1 is a protein
directly involved in atherogenesis through its role of recruiting macrophages to sites of infection
or inflammation (72, 122).
Although not demonstrated directly by blackberry flavonoids, select flavonoids have
been shown to play a protective role in platelet function which is critical in the pathogenesis of
cardiovascular disease (123). In vitro studies have shown that flavonoids reduce platelet
aggregation, decrease platelet production of superoxide anions and increase platelet nitric oxide
production (123).

Cancer
Evidence from epidemiological and clinical studies suggests that 20% or more of all
cancer cases are preventable with a diet consisting of 400 to 800 g of various vegetables and
fruits per day (75). Cancer is a complex multistage process that begins with initiation of a cancer
cell caused by DNA damage, accumulation of mutations, promotion of cell proliferation and
tumor expansion and finally progression to malignancy and metastasis (124). The potential role
of berry phenolic compounds to reduce cancer risk has been shown in in vitro, animal and
clinical studies (75). Berry phytochemicals may act to change the genomic stability of cells at
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several points along this sequence of cancer formation (124). The phytochemicals may modulate
initiation, promotion and progression of cancer (124). The possible anti-carcinogenesis
mechanisms include: antioxidant activity, detoxification activity, induction of apoptosis, antiproliferation, and anti-angiogenic activity (75). Anthocyanins have been reported to induce phase
II enzymes which may inactivate carcinogens activated by phase I enzymes therefore inhibiting
possible DNA damage by the carcinogens (75). Tate et al. (125) found that blackberry extracts
from 8 varieties: Arapaho, Choctaw, Hull, Chicksaw, Triple Crown, Kiowa, Navajo, and Chester
suppressed mutagenesis at varying levels. Mutagenesis is a process characterized by uncontrolled
cell proliferation and resistance to programmed cell death (124). Furthermore, blackberry
extracts prepared from 8 varieties inhibited UV-induced mutagenesis in Salmonella typhimurium
TA100 by 90% based on the Ames test (125). The Ames test is a good in vitro indicator of
mutagenic potential in vivo, with a 90% correlation between a positive response in assay and
carcinogenicity in animal models (125).
Serraino et al. (126) reported that blackberry extracts play a protective role against
peroxynitrite-induced DNA strand breakage in cultured human vascular endothelial cells. Using
blackberry extracts containing 80% cyanidin 3-glucoside the authors investigated the antioxidant
activity of the blackberry extract on the endothelial dysfunction in cells and in vascular rings
exposed to peroxynitrite. Blackberry extracts at varying dilutions reduced the peroxynitriteinduced suppression of mitochondrial respiration, and DNA damage in human umbilical vein
endothelial cells (126).
In addition, in vitro studies show that blackberry extract inhibits proliferation of A549
human lung cancer cells and reduced neoplastic transformation in normal epidermal JB6 mouse
cells exposed to the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), tumor promoter
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(124). Blackberry anthocyanins are thought to suppress cancer cell growth by modifying cell
signaling pathways such as modulating the expression of activated protein1 (AP-1) and nuclear
factor kappaB (NFκ B); important proteins that regulate cell proliferation and cell cycle control
(124). Blackberry extracts have also demonstrated inhibitory properties in cancer-induced AP-1
and NFκB and suppressed the expression of the two proteins involved in tumor promotion and
progression, vascular endothelial growth factor and COX-2 (124). Moreover, Seeram et al. (127)
has demonstrated the dose dependent cancer inhibitory properties of blackberry extracts in vitro
in a study that used human oral, breast, prostate and colon cancer cell lines. Similarly, a study
using quercetin extracted from blackberries also demonstrated the anti-carcinogenic properties in
animal models and in human carcinoma cell lines (HT29 and Caco-2) (75, 128).

Other health benefits
Studies on blackberries and their effect on body weight are lacking. However, cyanidin 3glycoside (which is the predominant anthocyanin in blackberries) from purple corn has been
shown to prevent obesity in C57BL/6J mice fed a high-fat diet compared to a mice fed high fat
diet with no anthocyanins (16). Similarly, purified blueberry anthocyanins have been shown to
improve body weights and body composition, and reduce obesity in mice (129). Although
matching health benefits may be expected from blackberry anthocyanins, their effects on obesity
need to be explored.
Blackberries are reported to have positive effects on age-related changes and may be
beneficial for prevention of age-related neurodegenerative diseases such as Alzheimer’s disease
(15). Shukitt-Hale and others demonstrated that 2% blackberry supplemented in the diet of 19month old Fischer rats was effective in improving motor performance on three balance and coordination tasks, and cognitive performance (15). Cyanidin 3-glucoside from blackberries was
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found in the brain of male Wistar rats after 15 days of feeding a 1.5% blackberry diet (130)
supporting the potential role of blackberry anthocyanins in neuroprotection.
Although the antimicrobial activities of blackberry tannins is not documented,
hydrolyzable tannins from red raspberries have shown antimicrobial activities on Staphylococcus
and Salmonella bacteria in animal studies (75). Since blackberries provide a rich source of ETs,
its anti-microbial properties should be investigated.
Blackberry anthocyanins in particular have not been studied in relation to diabetes;
however, there is evidence that in general anthocyanins can confer protective effects to the
vascular system in diabetic patients. Administration of anthocyanins from Bilberry (Vaccinium
myrtillus) at a dose of 600 mg/day for 6 months demonstrated significant reduction of
biosynthesis of polymeric collagen and structural glycoprotein that result in capillary thickness in
diabetes (131).
A study by Kaume and others (132) has recently demonstrated that supplementation of
blackberries at the level of 5% but not 10% in ovariectomized rats modestly increased bone
mineral density at the tibia by 2.4%, femur by 4.3%, and fourth lumbar vertebra by 2.7% higher
than ovariectomized control animals (P < 0.05). Further, animals fed 5% blackberry (w/w) had a
significant decrease in trabecular separation, by 22% less than the ovariectomized control rats.
More studies on the health benefits of blackberries on bone are necessary to elucidate on the
mechanism by which these berry compounds modulate bone metabolism.
Studies on blackberries reveal that their phenolic composition and concentration are
influenced by many factors including variety, location of cultivation, and maturation. The
chemistry of blackberry phenolic compounds is well understood. In terms of health benefits,
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these phenolic compounds have shown protective effects in age-related neurodegenerative
diseases, and bone loss in vivo, and inhibited LDL and liposomal oxidation in vitro. Blackberry
extracts have also exerted anti-mutagenic effects by modifying cell signaling pathways and
suppressing tumor promotion factors in vitro and in vivo. However, the anti-obesity, antidiabetic, antimicrobial, and anti-inflammatory properties of blackberry phenolic compounds
including catabolites from colonic microflora need investigation. In addition, more research is
needed to explore their metabolism, bioavailability and the mechanisms by which they confer
health benefits. Furthermore, studies that elucidate in vivo physiologically effective
concentrations of blackberry phenolic compounds in vivo are necessary.
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IV.

CYANIDIN 3-O-Β-D-GLUCOSIDE-RICH BLACKBERRIES IMPROVE
BONE MASS AND MICROARCHITECTURAL PROPERTIES IN AN
OVARIECTOMIZED RAT MODEL OF POSTMENOPAUSAL
OSTEOPOROSIS

ABSTRACT
Postmenopausal osteoporosis is characterized by fragility fractures and afflicts
approximately one third of women over 50 years. Oxidative stress promotes bone loss after
menopause, and there is evidence that dietary antioxidants may reduce the level of oxidative
stress in vivo. This study examined the dose dependent effects of blackberries (BB) containing
mainly cyanidin-3-O-D-glucoside (C3G) in preventing bone loss in an ovariectomized (Ovx) rat
model. Nine-month-old female (N=38) Sprague-Dawley rats were scanned using dual energy Xray absorptiometry to obtain baseline whole body, bone mineral content (BMC) and bone
mineral density (BMD). One group was sham-operated (Sham) and three groups were
ovariectomized (Ovx). The groups and corresponding diets were: Sham + control diet (n=12),
Ovx + control diet (n=12), Ovx + 5% BB (n=7), and Ovx + 10% BB (n=7). Control diet was
AIN-93M rodent diet, and the Ovx + 5% BB and Ovx + 10% BB were a diet modified to contain
powdered, freeze dried-BB at levels of 5 and 10% (w/w). Following 100 days of treatment,
whole body BMC and BMD were reassessed and bone specimens, and blood and 24h urine
samples were collected for analyses. Findings indicate that ovariectomy (Ovx) compromised
whole body BMC and trabecular microarchitecture of the proximal tibia and 4th lumbar vertebra.
C3G-rich BB at the level of 5% modestly protected BMDs loss of the tibia, lumbar vertebra, and
femur by 2.4, 2.7, and 4.3% respectively. BB5% treatment significantly prevented loss of tibial
trabecular bone volume and trabecular number by 37% and 21% respectively (p < 0.05); and also
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significantly prevented tibial trabecular separation by 22%. C3G-rich BB treatments had no
effects on both biomarkers of bone metabolism and oxidative stress. We conclude that C3G-rich
BB treatment at the level of 5% (w/w) may modestly reduce Ovx-induced bone loss evident by
improved tibial vertebral and femoral BMD values, and tibial bone microstructural parameters.
Bone protective effects may be as a result of the synergistic effects of phenolic compounds;
however, further work is required to determine blackberries’ specific mechanisms of action.

Key words: Postmenopausal osteoporosis; Blackberries; Polyphenols; Antioxidants; Cyanidin 3O-β-D-glucoside
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INTRODUCTION
Postmenopausal osteoporosis is characterized by fragility fractures and afflicts
approximately one out three women over 50 years1 Postmenopausal women experience increased
oxidative stress due to aging and estrogen loss2,3. Oxidative stress (OS) plays a major role in
activating osteoclastogenesis and promoting bone resorption in vitro and in rodent studies 4-7. As
a result of ovarian-hormone-deficiency osteoclasts increase the production of reactive oxygen
species (ROS), mainly superoxide anion and hydrogen peroxide 6, 8, 9. Heightened OS and
diminished levels of thiol antioxidant defenses in bone cells 7,10 induce production of proinflammatory factors such as interleukin 1 and 11 (IL-1 and IL-11) and tumor necrosis factor-α
that further aggravate the progression of osteoclastic activity 9-11.
The principal goal of osteoporosis therapy is to reduce fracture risk. To this end, drug
therapies such as alendronate, risedronate, zoledronic acid, denosumab and strontium ranelate
used with calcium and vitamin D have been effective 12. Nonetheless due to factors such as cost,
fear, and side effects associated with these drugs, about 50% of patients discontinue medication
or fail to adhere to treatments regimens in the first year of use, which results in increased fracture
risk 12, 13. Hence in addition to drugs and lifestyle modifications, practical diet-based approaches
to reduce the level of oxidative stress and improve bone health are necessary. Growing evidence
shows that increasing the intake of fruits and vegetables, as part of a nutrient-balanced diet, is
beneficial to bone health 14-18. Additionally, experiments with dietary antioxidants (e.g. N-acetyl
cysteine, ascorbic acid, alpha-tocopherol, and β-carotene) have demonstrated their potential to
promote bone formation 19 and increase levels of enzymatic antioxidants 7. These antioxidants
may stimulate osteoblast differentiation, suppress osteoclast formation, and decrease TNF-α
production, hence attenuate the bone resorptive effects of oxidative stress7, 19-22.
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Apart from the traditional dietary antioxidants such as vitamins A, C and E, phenolic
compounds from plums and blueberries have demonstrated protective effects against bone
resorption due to their strong superoxide scavenging capacity 23, 24,25. Akin to these fruits, is the
blackberry fruit (Rubus sp.) that has total phenolics range of 114 to 1056 mg/100 g fresh weight
(FW) 26. The composition of Blackberry (BB) includes anthocyanins 27, ellagitannins 28,
flavonols, flavan-3-ols 29, procyanidins 30, phenolic acids 26 and low amounts of lignans 31. Most
berries have several anthocyanins in their phenolic profile; however, BB contains mostly the
anthocyanin, cyanidin-3-glucoside (C3G) 32. The fraction of C3G in the whole blackberries used
in this study was 87%. According to studies 33-35 C3G has high anti-inflammatory and
antioxidative activity and has potential to play an important role in prevention of lipid
peroxidation of cell membranes.
Using an Ovx- rat model of postmenopausal osteoporosis, effects of supplementation
with C3G-rich blackberries at the level of 5% (w/w) and 10% (w/w) were assessed on: (i) bone
mineral density (BMD), (ii) trabecular microarchitecture (iii) bone biochemical markers, and (iv)
plasma enzymatic antioxidants.
MATERIALS AND METHODS
Animal care and diet
Nine-month-old female (N=38) Sprague-Dawley rats (Harlan, Indianapolis, IN) were
housed in an environmentally controlled animal care facility with standard temperature and light:
dark (12:12) cycles. Following a week of acclimatization the animals were randomly assigned to
four groups. One group was sham-operated (Sham) and three groups were ovariectomized (Ovx).
Baseline bone mineral density (BMD) and bone mineral content (BMC) were obtained using
DXA dual X-ray absorptiometry (DXA; GE Lunar DXA, Waukesha, WI) equipped with enCore
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software. The groups and corresponding diets were: Sham + control diet (n=12), Ovx + control
diet (n=12), Ovx + 5% BB (n=7), and Ovx + 10% BB (n=7). Control diet was AIN-93M rodent
diet, and the Ovx + 5% BB and Ovx + 10% BB were control diet modified to contain powdered,
freeze dried-BB at levels of 5 and 10% (w/w). Blackberry diets were formulated based on
proximate analysis of freeze-dried blackberries to contain the same amounts of carbohydrate,
fiber, fat and protein (data not shown). Rats were weighed on a weekly basis, received free
access to deionized water, and were match fed to the weekly mean food intake of the sham
group.
Animal necropsy
After 100-d treatment period, the animals were placed in metabolic cages for a 24 h
period in order to collect a 12-h urine sample. The urine sample was centrifuged at 3000×g for
20 minutes aliquoted and stored at -20 °C for deoxypyridinoline (DPD) and creatinine analyses.
After a12-hour fast, animals were anesthetized with a mixture of ketamine and xylazine (70 mg
and 3 mg/kg body weight, respectively) to measure final BMD and BMC using DXA. The rats
were then sacrificed by exsanguination via cardiac puncture. Blood samples were collected and
centrifuged at 3000×g for 20 minutes at 4 °C. Serum was aliquoted and stored at -80 °C until
analysis. Bone specimens, the tibiae, the 4th lumbar vertebrae and femur, were collected, cleaned,
and stored at -20°C for BMD and micro-architectural analyses. Uteri were collected and weighed
for confirmation of ovariectomy.
All animal procedures used in this study were according to the University of Arkansas
Institutional Animal Care and Use Committee guidelines.
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Assessment of bone mineral area, content, and density
Using procedures previously published 36and DXA equipped with suitable software for
assessing bone indices in small laboratory animals, bone mineral area (BMA), BMC and BMD
of the tibiae, the 4th lumbar vertebrae and femur were measured.
Assessment of bone microarchitecture using microcomputed tomography (μCT)
To assess the effect of C3G-rich blackberry treatment on bone trabecular structure, the tibiae, 4th
lumbar vertebrae and femur and were scanned using μCT and methods previously reported 37.
After analyzing the volume of interest (VOI), the following bone morphometric parameters were
obtained: bone volume over total volume (BV/TV), trabecular number (Tb.N.), separation
(Tb.Sp.), thickness (Tb.Th.), connectivity density, and structure model index (SMI).
Assessment of oxidative stress biomarkers
Effects of ovariectomy and C3G-rich blackberry treatments on oxidative stress levels were
assessed using four assays. Thiobarbituric Acid Reactive Substances (TBARS) were measured in
plasma and were used to determine lipid peroxidation 38, a major indicator of overall oxidative
stress. TBARS were determined in duplicate using TBARS assay kit (ZeptoMetrix Corporation
Buffalo NY, USA) according to manufacturer’s instructions and absorbance of 532 nm read on a
Synergy HT (BioTek; Winooski, VT) microplate reader.
The activity of antioxidant enzymes: glutathione peroxidase (GPx), superoxide dismutase
(SOD), and catalase were assessed in plasma using BioVision’s assay kits (BioVision Inc.
Mountain View, CA, USA) following manufacturer’s instructions. All samples were assayed in
duplicate and read using Synergy HT (BioTek; Winooski, VT) microplate reader.
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Assessment of systemic biomarkers bone metabolism
Effects of ovariectomy and the two doses of C3G-rich blackberry treatment were
evaluated in four systemic biomarkers of bone metabolism. Alkaline phosphatase (ALP) which is
required for the hydrolysis of phosphate esters was assessed in serum as an indicator of bone
formation using an Alfa Wassermann diagnostic technologies kit and ACE Alera clinical
chemistry system (Alfa Wassermann diagnostic technologies, West Caldwell, NJ, USA). Serum
osteocalcin (OC), a reliable indicator of bone turnover 39 was measured using Rat-MID™
Osteocalcin EIA (Immunodiagnostic Systems Inc. Fountain Hills, AZ, USA). Serum Insulin-like
growth factor-1(IGF-1), a recognized modulator of bone metabolism involved in proliferation of
osteoblasts 40was quantified using an enzyme immunoassay (EIA) kit from ALPCO
immunoassays (ALPCO Diagnostics, Salem NH, USA). In addition, a resorption bone biomarker
urinary deoxypyridinoline (DPD) was quantified using a competitive enzyme immunoassay kit
specific for rats (Quidel, Mountain View, CA, USA). The assay is established in DPD molecule
specificity and hence cross-reaction with other collagen crosslinks such as pyridinoline is highly
insignificant 41. Urinary creatinine was measured colorimetrically using an ACE Alera clinical
chemistry system and a commercially available kit from Alfa Wassermann diagnostic
technologies (Alfa Wassermann diagnostic technologies, West Caldwell, NJ, USA). The final
creatinine-corrected DPD results were expressed as nmols DPD/mmols creatinine. All serum and
urine samples were assayed in duplicates for the above biomarkers.

Statistical analyses
The data analysis involved estimation of means and SEM using JMP 8 (2009 SAS
Institute Inc. Cary, NC). The effects of treatment were analyzed by one-way ANOVA model
followed by post hoc analysis using the Fisher’s least squares means separation test when F
values were significantly different (P < 0.05).
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RESULTS
Bone mineral area, content, and density
Baseline BMC of the whole body was not different among groups; however, final BMC
of the OVX+BB10% and sham group was significantly lower than Ovx+control group. Baseline
BMD of the whole body were not different among groups. Effects of Ovx are observed as final
BMD values of ovariectomized rats were compared to the sham group (Table 4.1).
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Table 4.1. Effects of ovariectomy and C3G-rich blackberry treatments on DXA bone parameters of the whole body
Sham + Control
(n=12)

OVX + Control
(n=11)

OVX + BB 5%
(n=6)

OVX + BB 10%
(n=7)

P value

9.142 ± 0.223

9.191 ± 0.233

9.617 ± 0.316

9.186 ± 0.292

0.6424

(g/cm2)

0.174 ± 0.002

0.175 ± 0.002

0.179 ± 0.003

0.177 ± 0.003

0.4683

Final BMC (g)

9.975 ± 0.274a

11.564 ±0.287b

11.183 ± 0.379b

10.557 ± 0.359b

0.0026

Final BMD (g/cm2)

0.186 ± 0.002

0.178 ± 0.002

0.180 ± 0.003

0.182 ± 0.003

0.0833

Parameter
Whole Body
Baseline BMC (g)
Baseline BMD
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Values are means ± SEM. Within a row, values that do not share the same superscript letters are significantly
different from each other (P < 0.05). Abbreviations used: SHAM: Sham operated; OVX-CTRL: ovariectomized
control; OVX-BB 5%: Ovariectomized + blackberry 5% (w/w); OVX-BB 10% (w/w): Ovariectomized + blackberry
10% (w/w).

Table 4.2. Effects of ovariectomy and C3G-rich blackberry treatments on DXA bone parameters of the, tibia, 4th
lumbar vertebra and femur
Sham + Control
(n=12)

OVX + Control
(n=11)

OVX + BB 5%
(n=6)

OVX + BB 10%
(n=7)

P value

1.7425 ± 0.0264

1.6933 ± 0.0264

1.6667 ± 0.0671

1.6429 ± 0.0669

0.2795

BMC (g)

0.368 ± 0.007b

0.341 ± 0.007a

0.342 ± 0.012ab

0.324 ± 0.012a

0.0337

BMD (g/cm2)

0.211 ± 0.002c

0.200 ± 0.002ab

0.205 ± 0.003bc

0.196 ± 0.003a

0.0013

4th lumbar vertebra
BMA (cm2)

0.6267 ± 0.0120

0.5975 ± 0.0122

0.6100 ± 0.0177

0.5950 ± 0.0177

0.2592

BMC (g)

0.145 ± 0.0041

0.131 ± 0.0042

0.137 ± 0.0063

0.128 ± 0.0063

0.0540

BMD (g/cm2)

0.230 ± 0.004a

0.218 ± 0.004b

0.224 ± 0.005ab

0.214 ± 0.005b

0.0437

Femur
BMA (cm2)

1.9642 ± 0.0542

1.83 ± 0.0602

1.9217 ± 0.0435

1.9886 ± 0.0431

0.2588

BMC (g)

0.4460 ± 0.0140

0.410 ± 0.0140

0.452 ± 0.0190

0.430 ± 0.0190

0.2870

BMD (g/cm2)

0.2390 ± 0.0030c

0.224 ± 0.0030ab

0.234 ± 0.0043bc

0.215 ± 0.0043a

0.0004

Parameter
Tibia
BMA (cm2)
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Values are means ± SEM. Within a row, values that do not share the same superscript letters are significantly different from
each other (P < 0.05). Abbreviations used: SHAM: Sham operated OVX-CTRL: ovariectomized control OVX-BB 5%:
Ovariectomized + blackberry 5% (w/w); OVX-BB 10% (w/w): Ovariectomized + blackberry 10% (w/w).

There were no statistically significant differences in BMA of the tibia, 4th lumbar
vertebra and femur among groups but tibial BMC of the Ovx group was lower than the sham
group (Table 4.2). All three bones had BMA and BMC of the Ovx+control group lower to some
degree than the sham group although not to a statistically significant level. Tibial, vertebral and
femoral BMDs were significantly reduced by Ovx, 5%, 5% and 6% respectively. C3G-rich BB
diet at the level of 5% and not 10% (w/w) increased BMD of the tibia, lumbar vertebra, and
femur by 2.4%, 2.7% and 4.3% respectively compared to the Ovx+control, bringing it up to the
level of the sham group.
μCT analysis of tibia and fourth lumbar vertebra
Four cortical parameters were assessed at the proximal tibia, including cortical area,
porosity, thickness, and medullary area. Tibial cortical bone microarchitecture was markedly
compromised by Ovx (Table 4.3). Ovx resulted in decreased cortical thickness and cortical area
by 7% and 8% respectively, and an increase in cortical percent porosity of 8.5%.
C3G treatment at the level of 5% but not at 10% (w/w) increased cortical thickness by
5% bringing it up to the level of the sham group. C3G treatments had no impact on cortical area
and cortical porosity. Neither Ovx nor dietary treatments had any effects on cortical medullary
area.
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Table 4.3. Effects of ovariectomy and dose-dependent C3G-rich blackberry treatments on tibia cortical parameters

Parameter
Cortical bone

Sham + Control
(n=9)

OVX + Control
(n=8)

OVX + BB 5%
(n=6)

OVX + BB10%
(n=6)

P value

Cort Th (mm)

0.5932 ± 0.0113b

0.5538 ± 0.0113a

0.5820 ± 0.0123ab

0.5477 ± 0.0123a

0.0510

Cort Area (mm2)

4.5800 ± 0.1000

4.2400 ± 0.1100

4.3800 ± 0.1200

4.3200 ± 0.1200

0.1129

Med Area (mm2)

0.1849 ± 0.0046

0.1860 ± 0.0046

0.1873 ± 0.0050

0.1960 ± 0.0050

0.3293

Porosity (%)

3.880 ± 0.1300a

4.21 ± 0.1300ab

4.12 ± 0.1400ab

4.35 ± 0.1400b

0.1074
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Values are means ± SEM. Within a row, values that do not share the same superscript letters are significantly
different from each other (P < 0.05). Abbreviations used: SHAM: SHAM operated; OVX-CTRLovariectomized
control; OVX-BB 5% : Ovariectomized+blackberry 5%; OVX-BB 10% (w/w): Ovariectomized + blackberry 10 %
(w/w) Cort Th: cortical thickness; Cort: cortical; Med: medullary

Analysis of data also showed that Ovx considerably compromised all parameters of
trabecular microarchitecture of the proximal tibia and 4th lumbar vertebra (Figure 4.1) except
tibial Tb.Th. Ovx-induced changes were characterized by decreased BV/TV (Fig A), Tb.N. (Fig
B), and Tb.Th. (Fig C) and increased Tb.Sp. (Fig D). Ovx decreased tibial and vertebral BV/TV
by 23% and 13%, respectively. C3G-rich blackberry treatment at the level of 5% (w/w)
significantly increased tibial BV/TV by 37% and had no effect on lumbar BV/TV. The higher
dose of BB 10% (w/w) had a negative impact to vertebral BV/TV significantly reducing bone
volume by 28% compared to Ovx+control.
Similarly, tibial and vertebral Tb.N. was decreased in response to Ovx by 11% and 1.7%,
respectively. C3G-rich BB at the level of 5% (w/w) resulted in significant positive effects on
tibial but not vertebral Tb.N. Tibial Tb.N. values significantly increased by 21% in the
Ovx+BB5% group but the higher BB dose had no such effect. Ovx reduced Tb.Th. by 1.7% and
6.3% in the tibia and vertebra bones, respectively. In regard to treatments, the low BB diet dose
increased vertebra Tb.Th by 6% to the level of the sham group but the higher dose had no effect;
and neither treatments had an effect on tibial TbTh. Ovx also increased tibial and vertebra Tb.Sp.
by 17% and the slight 0.6% respectively. C3G-rich BB treatment at the level of 5% (w/w)
prevented tibial Tb.Sp. reducing it by 22%, bringing it up to the sham level; but the same dose
had no positive effects on the vertebral bone. Tibial and vertebral Tb.Sp in animals fed
blackberry at the level of 10% (w/w) was similar to the Ovx control group.
Non-metric parameters of the tibial and lumbar trabecular bone, i.e., SMI and
connectivity density (Figures 4.1E and 4.1F) were modified by Ovx albeit not to a statistically
significant degree. Higher SMI indicates a more biomechanically compromised trabecular bone
pattern which is more rod-like as opposed to the favorable plate-like pattern. Tibial SMI
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increased by 9.4%, and that of the vertebrae by 31%, while connectivity density decreased in
both bones by 32% and 2.6% respectively, due to Ovx. Though the impact of C3G-rich BB5%
(w/w) on tibial SMI did not reach significance level, this dose modestly prevented the change of
trabecular to the unfavorable rod-like pattern by reducing the index by 18% compared to
Ovx+control. The vertebra SMI was not changed by the lower dose of BB treatment but the high
dose significantly increased SMI. Tibial but not lumbar connectivity density in animals fed a
low dose of C3G-rich BB significantly increased to a value higher than the Ovx and sham
groups. The higher dose of C3G-rich BB treatment had no positive effects on connectivity
density of both bones.
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Figure 4.1. Effects of ovariectomy and dose-dependent C3G-rich blackberry treatments on tibia,

vertebrae and trabecular bone. Values are means ± SEM, bars that do not share the same letters

or numbers are significantly different (P < 0.05). Sham (n=9), OVX-Control (n=8) OVX-BB 5%

Biomarkers of oxidative stress and bone metabolism
Effects of Ovx and C3G-rich BB treatments were assessed on three antioxidant enzymes,
SOD, GPX, and catalase and a biomarker of oxidative stress, TBARS. Neither Ovx nor C3G-rich
BB treatments had any significant effects on these measures.
Urinary DPD and serum osteocalcin, ALP, IGF-I were measured to assess their response
to Ovx and C3G-rich BB treatments on bone resorption and bone formation, respectively (Table
4.4). DPD expressed per unit of creatinine was increased by Ovx, but C3G-rich BB treatments
did not suppress the urinary excretion of these collagen by-products. Serum osteocalcin was
significantly increased in the Ovx+control group (37%) in response to Ovx, but not altered by
C3G-rich BB treatments. ALP was significantly higher in the Ovx rats compared to the sham +
control group and C3G-rich BB treatment at the level of 10% but not 5% (w/w), decreased ALP
level the level of the sham group. In response to Ovx, IGF-1 increased by 9%, and C3G-rich BB
treatments further enhanced these levels in a dose dependent manner; however these changes
represent only a trend and did not reach the level of statistical significance.
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Table 4.4. Effects of ovariectomy and dose-dependent C3G-rich blackberry treatments
on antioxidant enzymes and systemic biomarkers of bone metabolism
Sham + Control OVX + Control OVX + BB5%
Parameter
(n=9)
(n=8)
(n=6)
a
b
DPD (nmol /mmol creatinine) 16.29 ± 3.41
37.29 ± 3.42
37.6 ± 3.87b

OVX + BB10%
(n=6)
31.2 ± 3.87b

Osteocalcin (ng/mL)

85.74 ± 19.46a

136.89 ± 19.47b 143.93 ± 25.16b

144.2 ± 25.16b

ALP (U/L)

34.82 ± 3.97

43.50 ± 3.98

47.83 ± 5.51

43.57 ± 5.51

IGF-1 (pg/mL)

12.14 ± 0.77

13.33 ± 0.78

13.47 ± 1.40

14.41 ± 1.40

Values are means ±SEM. Within a row, values that do not share the same superscript letters are
significantly different from each other (P < 0.05). Abbreviations used: SHAM: SHAM operated;
OVX-CTRLovariectomized control; OVX-BB 5% : Ovariectomized+blackberry 5%; OVX-BB
10% (w/w): Ovariectomized + blackberry 10 % (w/w); SOD: superoxide dismutase; GPX:
glutathione peroxide; TBARS: thiobarbituric acid reactive substances; DPD: deoxypyridinoline;
ALP: alkaline phosphatase; IGF: insulin-like growth factor
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DISCUSSION
Bone loss in response to Ovx is partially due to increased oxidative stress and impaired
antioxidant systems of the bone tissue 11, 42. In this study, bone loss occurred at all sites measured
in varying magnitudes. However, modest protection of tibial and femoral BMD by C3G-rich BB
5% (w/w) reduced fracture risk at these sites; the primary goal in osteoporosis therapy. Such
findings are encouraging considering that the risk of any fracture in women is about twice as
high as that of men 12. Similar bone protective effects have been demonstrated in blueberries
which have an equally high antioxidant capacity 17
Micro-CT analyses indicated Ovx -induced changes of the cortical and trabecular
microarchitecture as reported by others 15, 37, 43. Moreover, evaluation of the metaphyseal region
of the tibia demonstrated C3G-rich BB 5% (w/w)-protection against loss of BV/TV and Tb.N.
As a consequence of preserved Tb.N, less Tb.Sp. and more connectivity were observed. Tibial
Tb.Th. remained unaltered by both Ovx and treatment. We speculate that no effect on Tb.Th
resulted from a compensatory mechanism to correct for loss in connectivity as proposed
previously 37, and/or lack of statistical power due to limited sample size.
Rod-like trabeculae are more susceptible to fracture than plate-like patterns 44. Therefore
by preventing rod-like pattern formation as evidenced by lower SMI values, C3G-rich BB 5%
(w/w) reduced fracture risk. Such findings are important in providing evidence that supports
epidemiological studies 16, 45that associate consumption of fruits and vegetables to improved bone
health. Interestingly, response to treatment at the lumbar vertebrae was weak and these findings
agree with previous studies 37,46. However, compared to the proximal tibia this site was also less
vulnerable to the trabeculae deterioration effects of Ovx.
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In terms of biomarkers, concentrations of urinary DPD increased characteristic of bone
turnover in favor of resorption due to Ovx. However, C3G-rich BB diets did not suppress bone
resorption rate as would be expected. Also serum markers of bone formation ALP and
osteocalcin both of which indicated increased bone turnover following Ovx were unaltered by
BB treatment. Ovx and BB treatments had no effect on IGF-1. Suppression of Ovx-induced ALP
and osteocalcin has been reported in blueberry treatment 17 but not in dried plum 15. Similar to
dried plums treatment 15, C3G-rich BB diets were unable to alter bone mineralization raising the
question as to the mechanism of action. Systemic markers appear to differ with treatments and
mechanism of action; therefore further investigations are necessary to elucidate the mechanisms
by which C3G-rich BB prevent Ovx-induced bone loss.
Following Ovx, rats suffer depleted intracellular antioxidants, such as glutathione, and
experience increased osteoclast activity 11. Oxidative stress results in marked regulation and
expression of antioxidant enzymes including SOD, GPX and catalase 47. Overall, this study
found no significant changes in these enzymes as result of either Ovx or C3G-rich treatments.
However, a slight dose-dependent trend in reduction of SOD, GPX and catalase may be
indicative of reduced need for their expression due reduced oxidative stress by C3G-rich BB.
TBARS, an indicator of oxidative stress was reduced by C3G-rich BB 5% (w/w) but not 10%
(w/w) to levels similar to the sham group demonstrating the antioxidant potential of BB
phenolics.
Anthocyanin concentration in the blackberries in this study as determined by HPLC and
HPLC-ESI-MS was 631.3 mg/100 g of dry weight (DW) and cyanidin 3-O-β-D-glucoside was
87% of total anthocyanins. Therefore we can hypothesize that the bone protective effects seen in
this study are largely due to the high C3G content; which has one of the highest oxygen radical
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absorbance capacity activities (ORAC) recorded 48. It is plausible that the dose at 10% (w/w) was
excessive and therefore ineffective in combating oxidative stress. Also high fiber content in
blackberries may have inhibited the absorption of essential bone building minerals such as
calcium, phosphorous. However the mechanisms by which C3G-rich blackberries prevent bone
loss need to be explored in future studies. To our knowledge no other study has investigated the
bone-protective effects of blackberry phenolic compounds.
CONCLUSION
In conclusion, blackberries supplemented in the diet at the level of 5% (w/w) may
modestly reduce ovarian hormone-induced bone loss evident by improved tibial vertebral and
femoral BMD values, and tibial bone microstructural parameters. Bone protective effects may be
as a result of the synergistic effects of phenolic compounds; however, further work is required to
determine blackberries’ specific mechanisms of action.
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ANTIOXIDANT-RICH BERRIES EXERT MODEST BONE PROTECTIVE EFFECTS IN
POSTMENOPAUSAL SMOKERS WITHOUT IMPROVING BIOMARKERS OF BONE
METABOLISM
ABSTRACT
Smoking aggravates bone loss in postmenopausal women due to increased oxidative stress and
inflammation. Berries have shown bone protective effects in animal studies partially due to
antioxidant and anti-inflammatory properties of their phenolic compounds. We hypothesized that
consumption of 45g of blackberries or blueberries for 9 months will prevent smoking-induced
bone loss in postmenopausal women. Postmenopausal smokers (n=45) and nonsmokers (NS)
(n=20) were recruited. Smokers were randomly assigned to one of three treatment groups:
smoker control (S-C) n=21; smoker + 45 g freeze-dried blackberries (S-BB) n=8; or smoker + 45
g freeze-dried blueberries (S-BL) (n=16). We measured: bone mineral density (BMD) of total
body, and other regions at 0 and 9 mo., and urinary deoxypyridinoline, bone alkaline phosphate,
osteocalcin, thiobarbituric acid reactive substances and highly sensitive C-reactive protein at 0,
3, 6, and 9 month. Bone loss of total body BMD was statistically significant in S-C and S-BL
groups, but not in S-BB and NS-C groups (P = 0.0284). No significant changes were noted on
other parameters. These findings indicate that antioxidant rich blackberries but not blueberries
modestly protected against smoking-induced bone loss in postmenopausal smokers. The
mechanisms by which berries prevent bone loss need further exploration.
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INTRODUCTION
Postmenopausal osteoporosis is one of the most prevalent and debilitating bone diseases,
affecting over 200 million women worldwide 1. With regard to etiology and pathogenesis of
postmenopausal osteoporosis, oxidative stress and inflammation are established mechanisms
demonstrated in ovariectomized (Ovx) rats 2. Oxidative stress (OS) characterized by increased
osteoclast production of oxygen derived free radicals occurs as a consequence to lowered thiol
antioxidant defenses due estrogen loss 2,3. In response to elevated levels of OS, there occurs
increased expression of pro-inflammatory cytokines including, tumor necrosis factor-α (TNF-α)
. Jagger and others 3 have demonstrated that through TNF-α signaling, osteoclastogenesis is

3

stimulated and promoted in a rat model of postmenopausal osteoporosis.
In light of this, postmenopausal smokers have increased risk for osteoporosis 4 due to an
additional 1015 free radicals/g inhaled from cigarette smoke 5. Oxidants from cigarette smoke also
down-regulate the expression of important mediators of bone formation, osteocalcin, type 1
collagen and alkaline phosphatase that are essential for bone structure 6. In fact, smokers have 510% less bone than nonsmokers by the age of 45-50 years 7. Furthermore, smokers compared to
nonsmokers have elevated levels of plasma inflammatory factors, and lipid peroxidation
biomarkers 8.
Pharmacological therapies for postmenopausal osteoporosis are aimed at reducing future
fracture risk, they include: bisphosphonates, raloxifene, strontium ranelate, denosumab and
parathyroid hormone peptides 9. Though effective, both poor access and adherence to these
treatments have been reported 10, 11 Treatments such as insulin-growth factor-1, calcium, and
vitamin D have also demonstrated modest anabolic responses 12. Nonetheless, safe life-long
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preventive interventions need to be embraced in overcoming the burden of osteoporosis in
individuals and in the society.
Nutritional therapies using fruits and vegetables may also be effective in protecting
against bone loss as suggested by some epidemiological, clinical and animal studies 13-17. A
growing body of evidence proposes that besides the nutrients, phenolic compounds in fruits and
vegetables possess strong antioxidant and anti-inflammatory properties that can improve oxidant
states in vivo 18and exert health benefits.
With regard to fruits, dried plums, freeze-dried blueberries and freeze-dried blackberries
have demonstrated bone protective effects in Ovx rats 16, 17, 19. Furthermore, effects of dried plums
20

but not blackberries and blueberries on bone health have been explored in humans. The

phenolic composition of blackberries (BB) and blueberries (BL) consists mainly of anthocyanins,
flavonols, and chlorogenic acid (BL) and ellagitannins and ellagic acid (BB) 21. Anthocyanins are
known to be powerful antioxidants and make up a large proportion of these berries. However,
with regard to health benefits, we must consider possible synergetic effects from all berry
bioactive compounds and their metabolites.
Healthy postmenopausal smokers were used in the present study to test the hypothesis
that antioxidant-rich BB and BL can prevent smoking-induced bone loss. To this end, we
assessed the effects of BB and BL on: bone mineral density (BMD), and bone mineral content
(BMC), three biomarkers of bone metabolism, a biomarker of oxidative stress and a biomarker of
inflammation. To our knowledge, the present study is the first to explore bone health benefits in
postmenopausal smokers after BB and BL consumption.

122

PARTICIPANTS AND METHODS
Participants
Guidelines of the Declaration of Helsinki were followed when conducting this clinical study and
the clinical protocol was approved by the University of Arkansas Institutional Review
Committee (Fayetteville AR, USA). Participants had to be healthy, 1-10 years postmenopausal,
and not on hormone replacement therapy for at least 6 months before initiation of the study.
Participants were not on medication affecting calcium or bone metabolism, and have a BMD tscore above 2.5 SD of the mean at all sites. In addition, participants with chronic diseases
including skeletal disorders, diabetes mellitus, cardiovascular disease, gastrointestinal/digestive
problems, and respiratory problems, thyroid disorder, and impaired liver function were excluded.
Also excluded from the study were: participants on anabolic steroids, corticosteroids or
glucocorticoids, medications for bone, or hormone replacement therapy, and women consuming
a cup or more of blueberries or blackberries. A total of 212 women responded to advertisement
on local radio and newspaper, fliers, and brochures. Sixty five eligible women were enrolled in
the study. Participants signed an informed consent and completed a health and medical history
questionnaire related to the exclusion criteria. Recruited participants were smokers and
nonsmokers. Smokers (N=44) were defined as smoking daily and nonsmokers (N=21) were not
current smokers and none of those recruited had smoked in the previous 10 years.

Study design
The study design is summarized in Figure 5.1. Smokers were randomly assigned to one
of three groups: smoker control (n=21), smoker + 45 g/day freeze-dried blackberries (n=8), or
smoker + 45 g/day freeze-dried blueberries (n=16) and nonsmokers (n=20) was a control group.
Participants in berry groups were provided with 45 g BL and BB (WaterShed Foods Gridley, IL
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USA) pre-weighed and vacuum-packed in moisture-proof bags to ensure food safety, retention of
nutrition value, and for ease of storage and transportation. Participants were asked to consume 45
g of their respective berries daily. Participants on berry regimens were advised to adjust their
daily food intake to account for the energy provided by the freeze-dried berries. Calendars were
provided to record days on which berries were consumed and participants requested to return any
unused berries in preceding visits. At baseline and after 9 months, BMD was measured, and at
baseline, 3, 6 and 9 months, venous blood samples and 2nd void urine samples were collected.
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Figure 5.1. Study design showing the effects of daily consumption 45 g of freeze-dried blackberries and freeze-dried blueberries
studied in postmenopausal smokers during a 9 month intervention. Abbreviations used: S-BL: smokers + 45 g blueberries/day; S-BB:
smokers + 45 g blackberries/day; S-C: Smokers control group; NS-C: nonsmokers control group.

Nutrient and phenolic composition of freeze-dried berries
Macro and micro-nutrient composition of 45 g of FBB and FBL were analyzed by
Nutrition Pro® (Axxya Systems; Stafford, TX) software based on USDA references. Proximate
analyses of blackberries and blueberries were performed in duplicates by the Central Analytical
Laboratory at the University of Arkansas (Poultry Science Center, Fayetteville AR). In addition
flavonoid analysis of FBB and FBL was performed in triplicates using high performance liquid
chromatography (HPLC) confirmed by mass spectroscopy methods as described by Cho and
others 22.

Anthropometric measurements, dietary and physical activity assessment
At baseline, nutrition and medical histories were obtained from each participant by a
trained staff member. Similarly, anthropometric data were collected at 0, 3, 6 and 9 month visits
by the same trained staff member and a 114-item, 7-day food frequency questionnaire (FFQ) was
administered to assess dietary intake. Nutrition data was analyzed by Nutrition Pro® (Axxya
Systems; Stafford, TX) software based on USDA references. Nutrients of interest are presented
in Table 5.1. The Five-City Physical Activity Recall was used to assess participants’ seven-day
hours of physical activity, sleep and other domestic and occupational activities 23 at 0, 3, 6, and 9
month time intervals. Data collected was used to compute hours spent on physical activity (PA)
per week.

Bone biochemical measurements
Second void urine samples were collected, measured, aliquoted into 1 ml and stored at 20° C till analysis. Venous blood was obtained by a phlebotomist; 4 ml sample for plasma and 6
ml sample for serum after an overnight fast at baseline, 3, 6, and 9 months. Blood samples were
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centrifuged at 3500 g for 15 minutes at 4° C, and the resultant plasma and serum aliquoted into
200 µl samples and stored at -80° C till analyses. Urine samples were used in evaluation of
urinary deoxypyridinoline (DPD) which is biomarker of bone resorption. Urinary creatinine,
which is required to normalize urinary DPD, was measured using a calorimetric assay (Quidel
Corporation, San Diego, CA, USA). Two markers of bone turnover, serum bone-specific alkaline
phosphatase (BALP) and serum osteocalcin (OC) were assessed using Elisa kits (Quidel
Corporation, San Diego, CA, USA).

Assessment of oxidative stress and inflammation
Effects of berry treatments on oxidative stress levels were assessed using thiobarbituric
acid reactive substances (TBARS), a biomarker of lipid peroxidation. TBARS were determined
in duplicate using TBARS assay kit (Cayman Chemical; Ann Arbor, Michigan). To measure the
potential anti-inflammatory effects of FBL and FBB, high-sensitivity C-reactive protein (hsCRP)
was evaluated using a latex particle enhanced immuneturbidimetric assay measured on an ACE
Alera clinical chemistry system (Alfa Wasserman, Inc.; West Caldwell, NJ).

Bone density measurements
At the beginning and end of the treatment period, BMD and bone mineral content (BMC)
were obtained using dual X-ray absorptiometry (DXA; GE Lunar DXA, Waukesha, WI). The
densitometry was equipped with enCore software for whole body, lumbar spine (L1-L4), hip and
forearm BMD and BMC measurements. To ensure stability of the densitometer and accuracy of
the data, the apparatus was tested using phantom scans before every data acquisition.
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Statistical analysis
Since measurements were taken at four time points (months 0, 3, 6 and 9), a split plot
model was used with treatments (i.e. NS, S-C, and S-BL and S-BB groups) as whole plot and
time as a split plot. Least square means (LSM) were compared for significance and where
significant effects were determined, means were compared. Data are reported as LSM ± SEM
and statistical significance set at P < 0.05. Data analysis was done using ANOVA using PROC
MIXED in SAS (Version 9.2; SAS Institute, Cary, NC, USA). A 2 sample t-test was also done to
compare baseline whole body, lumbar spine, and femurs, and forearm BMD and BMC
measurements of smokers versus nonsmokers.
RESULTS
Macronutrient and phenolic composition of freeze-dried berries
Results of proximate analysis were as follows: carbohydrates 88.4% and 92.1%; crude
fiber 27.7% and 12.5%; protein 6.4% and 3.6%; and fat 6.3% and 2.3% for blackberry and
blueberry respectively. Percent carbohydrates were calculated using the formula: 100 – percent
protein –percent fat. The energy and macronutrients provided by 45 g of FBB and FBL
computed from these percentages in addition to those calculated by nutrition software are shown
on Table 5.1.
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Table 5.1. Nutrient and phenolic compounds composition of 45 g of freeze-dried blackberries and blueberries obtained by
Nutrition Pro® software, proximate analysis and HPLC analysis.
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Nutrients

Freeze-dried blackberries
Proximate
Calculated
analysis

Freeze-dried blueberries
Proximate
Calculated
analysis

Energy (kcal)

118.94

195.00

97.95

185

Total fat (g)

1.07

3.00

0.88

1.00

Total carbohydrates (g)

28.96

39.00

23.85

42.00

Protein(g)

1.84

3.00

1.52

2.00

Fiber (g)

10.44

12.00

8.6

6.00

Crude fiber (g)

5.59

-

4.61

-

Vitamin E (IU)

2.19

-

1.81

-

Vitamin A (RE)

26.41

-

21.75

-

Vitamin C (mg)

74.86

-

61.65

-

Folate (μg)

53.19

-

43.8

-

Ca (mg)

46.81

-

38.55

-

P (mg)

39.89

-

32.85

-

K (mg)

384.32

-

316.5

-

Fe (mg)

1.06

-

0.88

-

HPLC analysis

-

HPLC analysis

Phenolic composition*
Total anthocyanins (mg)

-

284.085 ± 3.915 -

652.14 ± 53.865

Total flavonols (mg)

-

33.48 ± 0.225

-

35.919 ± 3.06

Total ellagitannins (mg)

-

111.96 ± 0.72

-

-

Chlorogenic acid (mg)

-

-

-

72.9315 ± 1.89
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Calculated values from Nutrition Pro® (Axxya Systems, Stafford, TX); analysis based on USDA references. Proximate analyses
performed in duplicates by the Central Analytical Laboratory at the University of Arkansas. * HPLC phenolic composition performed
in triplicates; values are mean ± SEM

Estimates of the major phenolics consumed in 45 g of FBB and FBL per day are
summarized in Table 5.1. In terms of the phenolic profile of FBB, 5 different anthocyanins were
identified but approximately 87% of the anthocyanins were cyanidin-3-glucoside. In addition, 9
quercetin glycosides, and 4 ellagitannin compounds, were determined. Twenty nine different
phenolic compounds were identified in FBL. Of these, 17 were anthocyanins, mainly, cyanidin,
delphinidin, malvidin, peonidin, and petunidin glycosides. Six flavonols compounds determined
in FBL were quercetin and myricetin glycosides.

Participants
Fifty women completed the 9 month study but data used was for 49 of the participants
(31smokers and 18 nonsmokers). The overall attrition rate was 24.6%. The most common
reasons for dropping out of the study were: inconvenience (n=6), medical reasons (n=2),
relocation (n=1), and inability to consume berries as prescribed (n=5), and quit smoking (n=2).
Attrition was noted to be highest at the 3 month visit (n=11) compared to 6 month (n=3) and 9
month (n=2) visits. Attrition affected the experimental groups as follows: S-C, S-BB, S-BL and
NS reduced by 9, 2, 3 and 2, women respectively.

Baseline characteristics, anthropometric measurements, physical activity
measurements and dietary intake

Characteristics, anthropometrics measurements are presented by treatment group in
Table 5.2. The participants were predominantly white (98%) aged 46.5-68.0 years and the
median age was 54.5 years. Baseline characteristics were similar for all smokers in the study.
The average age of the NS-C was 4 years greater than each of the other experimental groups (p =
0.0166). All nonsmokers still fit the 1-10 years postmenopausal range specified for eligibility
131

into the study. Since PA improves bone function and strength, data was analyzed to detect
differences among experimental groups for number of hours spent on PA. No significant
differences existed in the activity levels of the women throughout the study period.
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Table 5.2.Baseline characteristics of study participants
Measures
Age (yrs)

NS-C (n=20) S-C (n=21) S-BB (n=8)
58.0 ± 0.9b
54.4 ± 0.9a 54.3 ± 1.6a

S-BL (n=16)
54.2 ± 1.1a

p value
0.0166

Years postmenopausal

7.4 ± 0.7

5.6 ± 0.7

6.9 ± 1.2

6.7 ± 0.8

0.2049

Weight (kg)

66.0 ± 3.8

72.9 ± 3.6

68.2 ± 6.5

76.5 ± 4.4

0.2980

BMI (Kg/m2)

23.7 ± 1.5

27.8 ± 1.4

25.2 ± 2.5

29.3 ± 1.7

0.1476

Physical activity (hrs/wk)

1.8 ± 0.3

1.6 ± 0.3

1.7 ± 0.6

1.59 ± 0.4

0.9533

Cigarettes/day

-

17.5 ± 1.7

17.9 ± 3.0

16.1 ± 2.1

0.7378

Body fat (%)

37.2 ± 1.7

41.5 ± 1.7

38.9 ± 3.8

40.2 ± 1.9

0.3668

Values represent means ± SEM. Values within a row that do not share the same letters are
significantly different from each other (P < 0.05). Abbreviations used: NS-C: Nonsmokers
control group; S-C: Smokers control group; S-BB: smokers + 45 g blackberries/day; S-BL:
smokers + 45 g blueberries/day. With the exception of age, there were no significant differences
observed between the experimental groups for these measures at 3, 6 and 9 months
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All P-values of time and treatments and their interaction derived from 7d FFQ data is
presented in Table 5.3. Treatment effect was significant for vitamin A intake. S-C, S-BL, and SBB groups consumed significantly lower amounts of vitamin A when compared to NS-C group.
Consumption of dietary fiber, vitamin E and vitamin D were significantly different based on
month and this may be due to seasonal variations. Means of total energy, vitamins and minerals
as analyzed from the FFQ are presented in Appendixes 3, 4 and 5.
Based on a 2000 kcal diet, 45 g of FBB and FBL were estimated to contribute 5.9% and
4.9%, respectively to participants’ total energy intake. Actual percent contribution of total energy
based on the mean total energy intakes was 5.6% and 4.8%, for FBB and FBL, respectively.
Blueberries had better acceptance than blackberries due to the large amounts of seeds in BB.
Nonetheless, both berries were well tolerated. The mean self-reported compliance for S-BL and
S-BL groups were 85% and 87% respectively.
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Table 5.3.Entries are p-values for the F-tests of treatments and time on daily total energy and nutrient intake in the
ANOVA.as calculated from a 7 d FFQ.
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Treatments

Total energy
0.7674

Protein
0.9698

Total fat
0.2577

Carbohydrates
0.6808

Dietary Fiber
0.1413

Time

0.7937

0.1896

0.9187

0.2770

0.0121

Treatment*Time

0.7403

0.8888

0.8099

0.7808

0.2183

Treatments

Vitamin C
0.3726

Vitamin A
0.0011

Vitamin E
0.0618

Vitamin K
0.4782

Vitamin D
0.0621

Time

0.0654

0.6624

0.0017

0.5234

0.0222

Treatment*Time

0.3151

0.8415

0.5920

0.6802

0.8145

Treatments

Calcium
0.1097

Magnesium
0.1045

Potassium
0.4291

Phosphorus
0.3482

Sodium
0.8963

Biotin
0.0929

Time

0.5182

0.5526

0.3170

0.4091

0.8335

0.4697

Treatment*Time

0.9053

0.8037

0.8676

0.9695

0.6778

0.2058

Treatments were: nonsmokers control group, smokers control group, smokers + 45 g blackberries/day and smokers + 45 g
blueberries/day. Time was 0, 3, 6, and 9 months, and treatment*time is the interaction of treatment and time. Significance was
established at p < 0.05.

Bone mineral density and content
A 2 sample t-test comparing baseline whole body, lumbar spine (L1-L4), hip and
forearm BMD and BMC measurements showed no significant differences between
smokers and nonsmokers (data not shown). After the 9 mo. treatment period, bone loss of
total body BMD was statistically significant in S-C and S-BL groups, but not in S-BB
and NS-C groups (P = 0.0284). Blackberries but not blueberries demonstrated modest
bone protective effects in preventing smoking-induced bone loss. Both freeze-dried fruit
regimens had no significant changes on BMC, and BMD of the lumbar spine, right and
left femur and ulna.

Biomarkers of bone metabolism, TBARS and hsCRP
Berry consumption had no significant effect on neither urinary nor serum biomarkers of
bone metabolism BAP and OC (Appendix 6). DPD is a stable product of lysine
breakdown during bone resorption. Though not to a significant degree, DPD levels
remained somewhat stable for the S-BB group, but slightly fluctuated over the nine
month periods for the other experimental groups. Similarly, this trend was observed with
the two serum biomarkers of bone turnover, BAP and OC for all groups.
Berry regimens had no significant effects on oxidative stress or inflammation
levels in postmenopausal smokers as shown on Appendix 7. Levels of plasma hsCRP, a
reliable marker of inflammation, fluctuated in the four experimental groups over 0, 3, 6,
and 9 month periods.
TBARS a biomarker of lipid peroxidation decreased in the S-BB and S-BL groups
and remained low thereafter compared to the levels in S-C and NS groups which
increased in a time dependent manner.
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DISCUSSION
There is paucity of studies regarding potential bone health benefits of blackberries
and blueberries. Nonetheless, two studies 16, 17 suggest that BB and BL may suppress bone
turnover and prevent bone loss in animal models.
Characteristic of ideal randomization, all smokers started with similar baseline
attributes and they remained unaffected by berry intervention throughout the study.
Considering data analyzed from the FFQ, there were two main observations: first, freezedried BB and BL supplied 12.5g and 6 g of fiber respectively which may have enhanced
weight control 24 and prevented weight gain. Secondly, vitamin A, known to suppress
bone resorption and stimulate bone formation 25, 26, 27 may have contributed to reduced
bone loss in N-SC group.
In terms of BMC and BMD, we propose that age of nonsmokers’ and lack of
statistical power due to small sample sizes were possible causes for lack of differences in
baseline BMD measures of smokers versus nonsmokers. However, as expected and
evidenced by reduced total BMC and BMDs at all sites, all experimental groups lost bone
within the 9 month period. However, S-C group lost significantly more bone mass than
the S- BB and NS-C group but not S-BL group. Notably, the ulna experienced more bone
loss than all other sites in all groups indicating increased fracture risk at this site. Overall
nonsmokers had the least percent bone loss which is consistent with epidemiological
findings that smoking aggravates bone loss 7. Findings of this study suggest that
blackberries showed modest bone protection of only total body BMD and blueberries had
no effect on bone health. Blackberries supplied 284 mg of ACY, 33 mg of flavonols and,
112 mg of ellagitannins daily while blueberries supplied 652 mg ACY, 36 mg flavonols
and 73 mg of chlorogenic acid daily. Although it is plausible that the ACY profile of the
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berries may be a major factor, BB just like BL did not have a profound effect on BMD in
other sites measured. These findings are contrary to others 20, 28 that demonstrate bone
health benefits of consuming fruits and vegetables. Nonetheless, since only smokers
received berries in this study the question remains as to whether these findings would be
similar in nonsmokers.
Mechanisms by which berries may exert health benefits were investigated by
measuring both markers of bone formation and bone resorption. Levels of BAP and OC,
now considered bone turnover markers 29-31 are generally correlated with bone mass and
describe rates of bone formation or resorption. Contrary to our expectations, berry
regimens had no effect on formation and resorption rates in postmenopausal smokers
matching the results of bone mass. In the S-BB group, levels of urinary DPD indicated a
reduced rate of bone breakdown albeit not to a significant degree. Nonetheless, we can
reasonably propose that the mechanism by which BBs prevented bone loss may involve
suppression of bone resorption. This is a mechanism that has been postulated in other
studies that have demonstrated protective effects of dried plum 19, 32.
Regarding oxidative stress, we expected that berry antioxidants would improve
the basal level of oxidation that accompanies normal cellular metabolism in smokers.
After three months of berry consumption, concentrations of TBARS in the berry groups
(irrespective of the berry type) remained stable compared to control groups. Although
this did not achieve statistical significance, it is indicative that berry regimens may
prevent oxidative stress in postmenopausal smokers. To strengthen the argument, we
observed that, TBARS concentrations in the control groups increased in time-dependent
fashion as expected due to smoking33 (S-C group ) and estrogen loss34(S-C and NS-C
groups). With respect to inflammation, smokers had higher levels of hsCRP, similar to
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findings by Gan et al., 35. Berry regimens did not suppress inflammation resulting from
smoking and postmenopausal status even though berry phenolic compounds and
anthocyanins in particular have demonstrated anti-inflammatory properties in animal
models 36, 37. Conflicting findings concerning effects of phenolic compounds are reported
in other studies 38,-40. Karlsen et al., 41 found no effect on CRP concentrations after daily
consumption of 300 mg/d of blueberry anthocyanins in a 3 week study using healthy
nonsmokers.
Overall, outcomes of this study are atypical due to growing evidence that dietary
antioxidants exert modest antioxidant effects in vivo and improve bone indices14, 16, 17, 42.
Berry intervention may have been affected by one or a combination of several factors: (i)
composition of gut microbiota in smokers receiving berries 43, (ii) our relatively small
treatment groups which affected statistical power, (iii) smoking status of participants, and
(iv) absorption and bioavailability of berry bioactive compounds and their metabolites
upon which potency is dependent. BB and BL absorption and metabolism though unclear,
is known to be different 40, 44, 45 and may influence health benefits.
CONCLUSION
In conclusion, the findings of this study and the existing literature on berry
bioactive compounds are conflicting. Blackberries demonstrated only modest protection
on total BMD and had no effect on other parameters; while and blueberries had no
positive effects on all parameters determined in postmenopausal smokers. Future studies
are necessary to explore mechanisms by which berries prevent bone loss and effective
doses in both postmenopausal smokers and nonsmokers.
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V.

SUMMARY AND CONCLUSIONS

This conclusions chapter gives a summary of each of the chapters of this
dissertation.
The introduction and literature review establishes that postmenopausal
osteoporosis is a public health burden that manifests in fragility fractures and affects over
200 million women worldwide 1. In the United States alone nearly half of all women over
the age of 50 suffer osteoporosis-related fractures, i.e. more than 1.5 million fractures a
year 2.
Additionally, smoking in postmenopausal women increases the risk factor of
osteoporosis 3 by reducing active vitamin D in plasma4, causing malabsorption of
calcium5, and increased oxidative stress6 and inflammation6, 7. Moreover, oxidants from
cigarette smoke down regulate the expression of important genes that mediate bone
formation and essential for bone structure 8.
Approximately 34,000 hip fractures that occur in the United States annually are
attributable to smoking 9. In addition, in females smoking can reduce bone mass at hip,
lumbar spine, forearm and calcaneus, and increase the lifetime risk of hip fracture and
lumbar spine by 31% and 13% respectively 7. Moerover, heavy smoking in women,
throughout adult life can result in 5-10% less bone by the age of 45-50 years, compared
to non-smokers 5.
Also, osteoporosis drug therapies fall into two categories: the antiresorptive
medications that slow the breakdown of bone and the anabolic treatments that help build
bone. These drugs are effective and work with the body systems to protect bone mineral
density and reduce the risk of fractures 10. However, due to several factors including cost,
fear, and side effects associated with these drugs, approximately 50% of patients
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discontinue medication or fail to adhere to treatments regimens in the first year of use 10,
11

.
The literature review emphasizes that phenolic compounds, particularly

anthocyanins and flavonols found in fruits and vegetables have antioxidative and antiinflammatory capacities 12. Hence, consumption of diets rich antioxidants is associated
with health benefits. Blueberry and blackberry phenolics function as antioxidants by
easily donating hydrogen atoms from their aromatic hydroxyl groups and by supporting
unpaired electrons 13.
The chapter on the review of blackberries reveals that blackberries are rich in
phenolic compounds and their composition and concentration is influenced by several
factors including variety, location of cultivation, and maturation. Blackberries are a rich
source of phenolics including, anthocyanins 18, ETs 19, flavonols 20, flavan-3-ols, and
procyanidins 21. The berries also contain appreciable levels of phenolic acids 22 and low
levels of lignans 23. Total phenolics in blackberries have been shown to range from 114 to
1056 mg/100 g fresh weight22.
Finally, the review demonstrates that blackberry phenolic compounds have
protective effects against age-related neurodegenerative diseases, and bone loss in vivo,
and inhibits LDL and liposomal oxidation in vitro. However, more research is needed to
explore their metabolism, bioavailability and the mechanisms by which they confer
health benefits. Furthermore, studies are necessary to elucidate the in vivo effective
concentrations of blackberry phenolic compounds.
The animal study was based on the hypothesis that lowering oxidative stress by
consumption of antioxidant rich foods may prevent bone loss by attenuating
osteoclastogenesis and bone resorption 14-17. Findings of the animal study demonstrate
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that blackberries supplemented in the diet at the level of 5% (w/w) may modestly reduce
ovarian hormone-induced bone loss. Although the mechanism is still unclear, it is
reasonable to speculate that the compounds work by lowering oxidative stress.
In chapter five, findings of the clinical study in which postmenopausal smokers
consumed 45g of blueberries or blackberries were inconclusive, showing only modest
protection on total BMD by blackberries and not blueberries. Effects of blackberry and
blueberry consumption on bone health need further elucidation in pre- and
postmenopausal smokers and nonsmokers.
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APPENDICES
Appendix 1. Health and Medical History Questionnaire
Subject ID: ____________________
Interviewer: ____________________

Date______________

Age________ Height_______ Weight________ BMI__________
I. Medical History
A. Skeletal Health
Personal history of skeletal disorders:
1. Not known ___________________
2. Yes: uncontrolled ________________
3. Yes: Medications _________________
4. Yes: Exercise program ___________________
5. Yes: Modified diet ________________
6. Yes: Surgery __________
7. Yes: Combined program __________
Give details _______________________________________________________
Type of Medication(s)_______________________________________________
Current dosage _________________ Years taken _________________________
How does this condition affect your activity?
Family history of skeletal disorders:
1.
2.
3.
4.
5.

None _____
One parent _____
Both parents _____
One close relative _____
More than one close relative _____

Relative(s) _______________________________________________
Comments: ______________________________________________
B. Cardiovascular Function
Personal history of cardiovascular disease:
1. Not known ___________________
2. Yes: uncontrolled ________________
3. Yes: Medications _________________
4. Yes: Exercise program ___________________
5. Yes: Modified diet ________________
6. Yes: Surgery __________
7. Yes: Combined program __________
Give details _______________________________________________________
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Type of Medication(s)_______________________________________________
Current dosage _________________ Years taken _________________________
How does this condition affect your activity?
Family history of cardiovascular disease:
1. None _____
2. One parent _____
3. Both parents _____
4. One close relative _____
5. More than one close relative _____
Relative(s) _______________________________________________
Comments: ______________________________________________
C. Hypertension
1. None known ___________________
2. Yes: uncontrolled ________________
3. Yes: Medications _________________
4. Yes: Exercise program ___________________
5. Yes: Modified diet ________________
6. Yes: Yes: combined program__________
7. Most recent blood pressure __________
Explain_______________________________________________________
Type of Medication(s)_______________________________________________
Current dosage _________________ Years taken _________________________
Ever taken thiazide diuretics? ____________
D. Diabetes
1. No record or indication _____
2. In past, but not now _____
3. Yes, well controlled _____
4. Yes, not controlled _____
Explain ____________________________________________________
Type of Medication(s)_________________________________________
Current dosage _____________________Years taken________________
How does this condition affect your activity? _______________________
E. Gastrointestinal/Digestive Problems
1. No record or indication _____
2. In past, but not now _____
3. Yes, well controlled _____
4. Yes, not controlled _____
Explain ____________________________________________________
Type of Medication(s)_________________________________________
Current dosage _____________________Years taken________________
Ever taken steroids (i.e., prednisone)? ______________________
Currently taking antacids? _______________________________
How does this condition affect your activity? ________________
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F. Liver Disease/ Problems
1. No record or indication _____
2. In past, but not now _____
3. Yes, well controlled _____
4. Yes, not controlled _____
Explain ____________________________________________________
Type of Medication(s)_________________________________________
Current dosage _____________________Years taken________________
How does this condition affect your activity? _______________________
G. Respiratory Problems
1. No record or indication _____
2. In past, but not now _____
3. Yes, well controlled _____
4. Yes, not controlled _____
Explain ____________________________________________________
Type of Medication(s)_________________________________________
Current dosage _____________________Years taken________________
How does this condition affect your activity? _______________________
H. Thyroid Disorder
1. No record or indication _____
2. In past, but not now _____
Hyper? _____
Hypo? ___
Explain ____________________________________________________
Type of Medication(s)_________________________________________
Ever taken thyroid hormones (i.e., Synthroid)? _____
I.

Reproductive history: LMP_____________, No. of children______________

II. Medication or Drug Use
A. Previous or Present Use of Any of the Following (Specify):
1. Anabolic steroids _____________
2. Corticosteroids or glucocorticoids _____prednisone _____
3. Thiazide diuretics _____ Other diuretics _____
4. Vitamin D
5. Medications for bone
Fosamax:
Evista (Roloxaphin): ___________________
Miacalcin (Calcitonin): _________________
Teriparatide (Forteo):___________________
6. Others:
___________________________________________________
___________________________________________________
___________________________________________________

B. Previous or Present Use of Alcoholic Beverages (Beer, wine, hard liquor).
Please indicate:
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Frequency of intake (Times/week or times/month): _____
Number of servings at a sitting: _____
Number of years of use: _____
C.

Estrogen or Hormone Replacement (ERT or HRT)
1. Never ___ move along to section D.
2. Yes, in past ___ at what age? ___ & How long _____

D. Currently /previously a smoker?______If yes, number of cigarettes per
day____________
III. Physical Activity
A. Occupational Intensity (respond to 1, 2, 3, or 4):
1. Majority of time: Sitting ___ Standing ___ Walking ___
2. Equal amount of time:
Sitting and Standing ___
Walking and Sitting ___
Standing and Walking ___
3. Combination: Sitting, Standing, and Walking ___
4. Much of time: Lifting & Carrying ___
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Appendix 2. Telephone Screening Exclusion Criteria
Effect of Dried Fruits on Indices of Bone Status in Postmenopausal Women
Interviewer: study coordinator or trained personnel
Hello,
Good morning/good afternoon/good evening
How are you?
Thank you for your interest in our study
Is it a good time for me to go over a few questions with you now?
Are you a postmenopausal woman? If yes, when was your last period?
Do you know if you have current or previous history of:
Bone disorders (osteomalacia, severe osteoporosis, unexplained or stress fractures)
cancer
Diabetes mellitus (only Insulin Dependent)
Eating disorders (anorexia nervosa or bulemia)
Gastrointestinal or chronic digestive disorders (chrohn’s disease, ulcerative collitis)
Hypertension (exclude if taking thiazide diuretics)
Active liver disease
Parathyroid disorders
Renal disease/problems
Thyroid disease/problem
Other current illnesses?
Are you taking or have taken any of the following medications since the time of cessation of
your menses?
Glucocorticoids
Anabolic steroids (testosterone,
androgens)
Anticonvulsants
Current use of oral contraceptives
Calcitonin
Progestagens, progesterone (HRT)
Bisphosphonates
Estrogens (estrase, premarin,
prempro)
Teriparatide (Forteo)
Recent (<6 months) initiation on of thyroid
hormones
Are you a smoker? If so, how many cigarettes per day?
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Appendix 3. Seven Day Food Frequency Questionnaire
Subject Number_________

Date_________

Vitamin and Mineral Supplement
1. Do you take any vitamin or mineral supplement(s)?

Yes ___No _____

2. If Yes, please, list all names of vitamin or mineral supplements, and how often do you take
the supplement(s)?
Name ______________________ How often ____ per day Or ____ per week
Name ______________________ How often ____ per day Or ____ per week
Name ______________________ How often ____ per day Or ____ per week
Name ______________________ How often ____ per day Or ____ per week
Name ______________________ How often ____ per day Or ____ per week
This questionnaire asks you about your consumption of foods and beverages over the past week,
which includes the time from exactly one week ago until the last meal you had before you fill out
this questionnaire. The “How Often” columns are for day, week, or rarely/never. We want you
to think back over the past week and tell us how many times (per day, if you consume the item
every day, or per week) you consumed each item. A medium serving is in parentheses.
EXAMPLES:
Ate 1/2 grapefruit about twice last week.
Ate 1 large hamburger four times last week.
Drank 2 cups of whole milk each day.
Type of Food
(Medium Serving)
Grapefruit (1/2)
Hamburger, regular (1 patty, 3 oz)
Whole milk (1 cup, 8 oz)
Type of Food
(Medium Serving)

How Often
Day
Week

Rarely/
Never

2
4

Size
S M L
X
X

2

X

How Often
Day
Week

DAIRY FOODS
Whole milk (1 cup, 8 oz)
2% milk (1cup, 8 oz)
Skim milk (1 cup, 8 oz)
Cream, whipped (1 Tbsp)
Sour cream (1 Tbsp)
Coffee cream (1 Tbsp)
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Rarely/
Never

Size
S M L

Ice cream (½ cup)
Low fat ice cream (½ cup)
Frozen yogurt (½ cup)
Yogurt (1 cup)
Low fat yogurt (1 cup)
Cottage cheese (½ cup)
Cream cheese (1 oz)
Low fat cream cheese (1 oz)
Other cheese (1 slice or 1 oz)
Low fat cheese (1 slice or 1 oz)
Margarine (1 tsp)
Butter (1 tsp)
Reduced fat margarine (1 tsp)
FRUITS, FRUIT JUICES
Raisins (1 oz or 1 sm box)
Grapes (20)
Prunes (½ cup)
Bananas
Cantaloupe (¼ melon)
Watermelon (1 slice)
Apples, applesauce or pears
(1 fresh, ½ cup)
Dried Apples (1 oz)
Apple juice (½ cup)
Oranges
Orange juice (½ cup)
Grapefruit (½ cup)
Grapefruit juice (½ cup)
Other fruit juices (½ cup)
Strawberries—fresh, frozen, or canned
(½ cup)
Blueberries—fresh, frozen, or canned
(½ cup)

Type of Food
(Medium Serving)

How Often
Day
Week

Peaches (1 fresh, ½ cup canned)
Apricots (1 fresh, ½ cup canned)
Plums (1 fresh, ½ cup canned)
Honeydew melon (¼ melon)
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Rarely/
Never

Size
S M L

VEGETABLES,
VEGETABLE JUICE
Tomatoes (1)
Tomato juice (½ cup)
Tomato sauce (½ cup)
Spaghetti sauce (½ cup)
Red chili sauce, taco sauce, or salsa
(1 Tbsp)
Tofu or soybeans (3-4 oz)
String beans, green beans (½ cup)
Broccoli (½ cup)
Cabbage (½ cup)
Cole slaw (½ cup)
Cauliflower (½ cup)
Brussels sprouts (½ cup)
Carrots, raw (½ carrot or 2-4 sticks)
Carrots, cooked (½ cup)
Corn (1 ear or ½ cup frozen or canned)
Peas (½ cup fresh, frozen or canned)
Lima beans (½ cup frozen, or canned)
Mixed vegetables (½ cup)
Beans or lentils, baked or dried (½ cup)
Summer or yellow squash (½cup)
Winter squash (½ cup)
Zucchini (½ cup)
Yam or sweet potato (½ cup)
Spinach, (cooked ½ cup, raw 1 cup)
Iceberg lettuce, romaine or leaf (1 cup)
Celery (4” stick)
Beets (½ cup)
Alfalfa sprouts (½ cup)
Kale, mustard, or chard greens (½ cup)
Vegetable, vegetable beef, minestrone
or tomato soup (1 cup)

Type of Food
(Medium Serving)

How Often
Day
Week

EGGS, MEAT, ETC.
Eggs (2)
Chicken or turkey, roasted or broiled
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Rarely/
Never

Size
S M

L

with skin (3-4 oz)
Chicken or turkey, roasted or broiled
skinless (3-4 oz)
Chicken, fried with skin (3-4 oz)
Bacon (2 slices)
Hot dogs (2)
Low fat hot dogs (2)
Sausage (2 patties or 2 links)
Bologna (1 slice)
Other processed luncheon meat (1 slice)
Liver, chicken or beef (3-4 oz)
Hamburger, regular (1 patty, 3-4 oz)
Hamburger, lean (1 patty, 3-4 oz)
Meat loaf (3-4 oz)
Pork, chops, roasts (3-4 oz)
Lamb (3-4 oz)
Beef, roast, steak (3-4 oz)
Beef stew with vegetables (1 cup)
Ham (3-4 oz)
Tuna fish (3-4 oz)
Tuna salad (½ cup)
Fish, baked or broiled (3-4 oz)
Fish, fried or fish sandwich (3-4 oz)
Shrimp, Lobster, Scallops
Pizza (2 slices)
Mixed dishes with cheese (1 cup)
Lasagna or meat pasta dishes (1 cup)
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Type of Food
(Medium Serving)

How Often
Day
Week

BREADS, CEREALS, STARCHES
Cold breakfast cereal (1 cup)
Cold breakfast cereal—fortified (1 cup)
Cooked oatmeal (1 cup)
Other cooked breakfast cereal (1 cup)
White bread (1 slice)
Pita bread (1 piece)
Dark bread (1 slice)
English muffin (1)
Bagel (1)
Dinner roll (1)
Hamburger or hotdog bun (1)
Muffin (1)
Biscuit (1)
Corn bread, corn muffin (1)
Brown rice (1cup)
White rice (1cup)
Spaghetti noodles (1 cup)
Macaroni noodles (1 cup)
Other pasta noodles (1 cup)
Bulgar, kasha, couscous (1 cup)
Pancakes or waffles (2)
Potatoes, french fries or fried (½ cup)
Potatoes, baked or boiled (1)
Mashed potatoes (1 cup)
Potato chips or corn chips
(small bag or 1 oz)
Saltine crackers (5)
Saltine crackers, low sodium (5)
Saltine crackers, fat free (5)
Other crackers (5)
Other crackers, low fat (5)
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Rarely/
Never

Size
S M L

Type of Food
(Medium Serving)

How Often
Day
Week

BEVERAGES
Regular soft drink (1)
Diet soft drink (1)
Caffeine free soft drink (1)
Caffeine free, Diet soft drink (1)
Lemonade or other non-carbonated drink
(1 glass, bottle, or can)
Water (1 cup)
Coffee (1 cup)
Decaffeinated coffee (1 cup)
Tea (1 cup)
Herbal tea (1 cup)
Beer (1 glass, bottle, or can)
Red wine (4 oz glass)
White wine (4 oz glass)
Whiskey, gin, or other liquor
(1 drink or shot)
SWEETS, BAKED GOODS, MISC.
Chocolate (1 small bar or 1 oz)
Candy bar (1 small bar)
Candy without chocolate (1 oz)
Cookies, home baked (2)
Cookies, ready-made (2)
Brownies (2)
Doughnuts (2)
Cake, home baked (1 slice)
Cake, ready-made (1 slice)
Sweet roll, coffee cake, or other pastry
ready-made (1 serving)
Sweet roll, coffee cake, or other pastry
home baked (1 serving)
Pie, homemade (1 slice)
Pie, readymade (1 slice)
Jam, jelly, preserves, syrup, or Honey (1
Tbsp)
Peanut butter (1 Tbsp)
Popcorn (1 cup)
Popcorn, air popped (1 cup)
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Rarely/
Never

Size
S M L

Type of Food
(Medium Serving)

How Often
Day
Week

Rarely/
Never

Size
S M L

Nuts (small packet or 1 oz)
Bran, added to food (1 Tbsp)
Wheat germ (1 Tbsp)
Chowder or cream soup (1 cup)
Oil and vinegar dressing (1 Tbsp)
Mayonnaise or other creamy salad dressing,
Regular (1 Tbsp)
Mayonnaise or other creamy salad dressing,
Low Fat or Reduced Calorie, Lite (1 Tbsp)
Mayonnaise or other creamy salad dressing,
Fat Free (1 Tbsp)
Mustard, dry or prepared (1 tsp)
Salt (1 shake)
Pepper (1 shake)
Can you think of any other food or drink that you had in the past week that was not on this form?
If so, what was it? What was the amount? How many times did you have it this past week?

Food_________________________________________________________________________
Amount_________________, How often per day_____________, per week__________

Food_________________________________________________________________________
Amount_________________, How often per day_____________, per week__________

Food_________________________________________________________________________
Amount_________________, How often per day_____________, per week__________
Food_________________________________________________________________________
Amount_________________, How often per day_____________, per week__________
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Nutrition History Questionnaire
Subject ID:_________________
Interviewer:_________________
Effect of Dried Fruits on Indices of Bone Status in Postmenopausal Women
Date:______________________

Nutrition History
Modified/Specialized Diet(s)
Followed:___________________________________________________
Recommended By___________________ Length of time Followed______________________
Recent Changes in Appetite?_________________ Due to______________________________
Foods Avoided?___________________________ Due to______________________________
History of Problems Digesting Milk?________ When?________ How Long?_______________
Diagnosis of Lactose Intolerance?__________ When?________ By whom? __________
Intake of Milk/Dairy Products & Calcium-Containing Foods (No Times/Day, Wk or Month,
Portion Size):
Milk_______________ Yogurt__________________ Frozen Yogurt_____________________
Ice Cream/Milk__________ Pudding/Custard__________ Hard Cheese___________________
Mixed Dishes with Cheese_________ Soft Cheese__________ Grated Cheese______________
Donuts/Cakes/Cookies____________ Eggs______________ Dark Breads_________________
How has this intake changed during that past three years?
Intake of High Fiber Foods (Specify Type, No Times/Day, Week or Month, Portion Size):
Whole Grain Products: Breads___________________ Bran (wheat, oat)___________________
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Cereals_______________ Crackers___________ Grains (i.e., popcorn)____________
Nuts_____________________ Seeds____________________ Fruits____________________
Dried Fruits (prunes/dried apples)____________Vegetables__________________________
Beans/Legumes (i.e., chili)____________________
How has this intake changed during the past three years?
Nutritional Supplements (Type, Dose, Times/Week, No Years):
Vitamin Supplements___________________________________________________________
Mineral Supplements___________________________________________________________
Vitamin/Mineral Supplements____________________________________________________
Other Supplements (e.g., cod liver oil, protein powder)__________________________________

Daily Intake (Typical weekday)
Time Food/Description

Serving Size

Food Code

Sodium Intake (amount of salt used (tsp)/day): in cooking_________ at the table__________
Estimate of Na+ Intake/Day: Salt Shaker_____________ High Na+ foods:_________________
Beverages Consumed (servings per day):
Coffee: reg__________ decaf___________ Cocoa:_________ Tea: reg______ decaf______
Soda: reg (+caf)_________ diet(+caf)_________ reg (caf free)________ diet (caf
free)______
Milk (oz/day): reg (3.5%)__________ low fat (2%)___________ skim(1% or1%)__________
During what period(s) of life have you been a milk drinker? As a(n):
____1. Child ____2. Teenager ____3. Young adult (20-29) ____4. Adult (30-39)
____5. mid-life adult (40-59) ____6. Older adult (60+)
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____7. Never

If you excluded milk during any part of your life, was (is) this due to digestive problems?
(Explain):_______________________________________________________________
Milk consumed/day: child_____ teenager_____ young adult (20-29)_____ adult (30-39)_____
mid-life adult (40-59)_____ older adult (60+)_____Juice (type): _____________ Calcium
fortified Juice: _______________ Other:___________
Alcoholic Beverages:_________ If yes, please specify:
Type Times/week or Mo

Serving Size No Servings

Total/Week or Mo

Beer: Reg
Lite
Dark
Wine: White
Red
Rose
(Blush)
Mixed Drink (specify):
Other (specify):

How did your food or beverage intake differ from the above during your younger years (teenager
and young adulthood)?
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Appendix 4. Physical Activity Recall Items
Subject ID: _________________
Date: ______________________

Interviewer: ________________

First we would like to know about your physical activity during the past 7 days. But first, let me
ask you about your sleep habits.
1. On the average, how many hours did you sleep each night during the last five weekday nights
(Sunday-Thursday)? ______hours
2. On the average, how many hours did you sleep each night last Friday and Saturday nights?
_____hours
Now I am going to ask you about your physical activity during the past 7 days, that is, the last 5
weekdays and last weekend, Saturday and Sunday.
We are not going to talk about light activities such as slow walking, light housework, or nonstrenuous sports such as bowling, archery, or softball.
Please look at this list which shows some examples of what we consider moderate, hard, and
very hard activities. (interviewer: hand subject the following card and allow time for the
subject to read it over.)
People engage in many other types of activities, and if you are not sure where one of your
activities fits, please ask me about it.
3.

First, let’s consider moderate activities. What activities did you do and how many total
hours did you spend during the last 5 weekdays doing these moderate activities or others like
them?
Please tell me to the nearest half-hour. _____hours

4. Last Saturday and Sunday, how many hours did you spend on moderate activities and what
did you do?
(Probe: Can you think of any other sports, job, or household activities that would fit into this
category?)
_____hours
5. Now, let’s look at hard activities. What activities did you do and how many total hours did
you spend during the last 5 weekdays doing these hard activities or others like them?
Please tell me to the nearest half-hour. _____hours
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6. Last Saturday and Sunday, how many hours did you spend on hard activities and what did
you do?
(Probe: Can you think of any other sports, job, or household activities that would fit into this
category?)
________ hours
7. Now, let’s look at very hard activities. What activities did you do and how many total hours
did you spend during the last 5 weekdays doing these very hard activities or others like them?
Please tell me to the nearest half-hour.
(Probe: Can you think of any other sports, job, or household activities that would fit into this
category?)
_________ hours
8. Last Saturday and Sunday, how many hours did you spend on very hard activities and what
did you do?
(Probe: Can you think of any other sports, job, or household activities that would fit into this
category?)
_________ hours
9. Compared with your physical activity over the past 3 months, was last week’s physical
activity more, or less, or about the same?
_____ 1. More
_____ 2. Less
_____ 3. About the same
Interviewer: Please list below any activities reported by the subject, which you don’t know how
to classify. Flag this record for review and completion.
Activity(brief description)

Hours: workday

Hours: weekend day

______________________
______________________
______________________
______________________

______________________
______________________
______________________
______________________

______________________
______________________
______________________
______________________
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Occupational
Tasks:

Examples of Activities in Each Category
Moderate activity (3-5 mets)
1) Delivering mail or patrolling on foot
2) House painting
3) Truck driving (making deliveries, lifting/carrying light objects

Household
Activities:

1)
2)
3)
4)

Sports:
(actual playing
time)

1) Table tennis or Ping-Pong
2) Softball, baseball
3) Volleyball
4) Dancing: folk, square, aerobics (low impact & intensity)
5) Brisk walking (3 to 4 mile/hr; 15-20 min/mile)
6) Bicycling on level ground (10-15 mile/hr)
7) Golfing (walking and pulling/carrying own clubs)
Calisthenics exercise and weight lifting
Hard Activity (5.1 – 6.9 METS)
1) Heavy carpentry
2) Construction work

Occupational
Tasks:

Sweeping, mopping, cleaning windows
Mowing the lawn with a power mower
Raking the lawn and yardwork
Light carpentry

Household
Tasks:

1) Scrubbing floors
2) Shoveling snow
3) Moving (lifting furniture and boxes)

Sports:
(actual playing
time)

1) Racket Sports: badminton, paddleball, tennis (double)
2) Basketball
3) Rowing or canoeing leisurely
4) Dancing: disco, jazz, aerobics (medium impact & intensity
5) Power walking (>mile/hr; <15 min/mile) or hiking
6) Vigorous bicycling (16 – 20 mile/hr
7) Jogging (5 mile/hr)
8) Swimming
9) Roller or ice skating
10) Stationary bicycling
Very Hard Activity (7.0 METS)
1) Digging or chopping with heavy tools
2) Carrying heavy loads, such as bricks or lumber

Occupational
Tasks:
Sports
(actual playing
time)

1)
2)
3)
4)

Racket Sports: handball, racketball, squash, tennis (singles)
Soccer
Snow skiing (downhill and cross country)
Dancing: aerobics (high impact & intensity)
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5) Jumping rope
6) Vigorous bicycling on hillsJogging or running (8 mile/hr)
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Physical Activity Recall
1.

______ HOURS week-day sleep

2.

______ HOURS week-end sleep

3.

______ HOURS week-day moderate/5 = _______

4.

______ HOURS week-end moderate/2 = _______

5.

______ HOURS week-day hard/5 = ________

6.

______ HOURS week-end hard/2 = ________

7.

______ HOURS week-day very hard/5 = _______

8.

______ HOURS week-end very hard/2 = _______

9.

1 _____ 2 ______ 3 _____

Total (sum of #1 and #2) _____

1. Total sleep hours _____ x 1 = ______

2. Average = hours moderate act.______ x 4 = ______

3. Average = hours hard act. _____x 6 =
_______
4. Average = hours very hard act. ______ x 10 = ______

5. Sum of hours ______ - 24 _____x 1.5
10.

= ________

Sum of 1,2,3,4, & 5
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Appendix 5. Daily Total Energy and Macro-nutrient Intake Calculated from a 7 D
FFQ of Control Smokers and Nonsmokers, and Smokers Consuming 45 g of
Blackberries and Blueberries at Baseline, 3, 6 and 9 Months.
Month

NS-C

S-C

S-BB

S-BL

0

2051.5 ± 142.5

1818.7 ± 206.9

2095.8 ± 212.1

2051.6 ± 154.7

3

1997.8 ± 176.4

1789.9 ± 158.4

2367.5 ± 95.8

2141.8 ± 286.5

6

2253.8 ± 257.0

1957.4 ± 277.9

2217.3 ± 254.2

1939.5 ± 147.0

9

2139.9 ± 196.2

1953.6 ± 235.1

1855.6 ± 299.8

2026.4 ± 231.5

0

89.0 ± 6.0

93.1 ± 13.1

88.7 ± 4.4

88.6 ± 11.3

3

82.2 ± 6.4

79.9 ± 7.8

91.0 ± 3.6

88.7 ± 16.7

6

86.2 ± 6.6

80.0 ± 11.7

87.9 ± 13.0

71.5 ± 5.5

9

84.0 ± 5.9

82.0 ± 11.2

71.0 ± 14.7

76.1 ± 9.3

0

89.2 ± 8.7

72.8 ± 10.8

88.7 ± 14.7

84.0 ± 10.0

3

87.2 ± 9.3

68.3 ± 11.1

95.1 ± 14.7

87.0 ± 10.0

6

103.9 ± 9.7

73.3 ± 11.1

93.5 ± 15.6

77.4 ± 10.3

9

96.0 ± 9.3

76.3 ± 11.5

79.2 ± 15.6

79.6 ± 10.6

0

240.5 ± 20.1

196.7 ± 24.9

223.6 ± 34.0

219.2 ± 23.2

3

242.0 ± 21.2

200.8 ± 25.6

266.0 ± 34.0

261.8 ± 23.2

6

242.6 ± 22.0

229.9 ± 25.6

230.4 ± 35.6

250.9 ± 23.7

9

236.8 ± 21.2

224.4 ± 26.3

236.5 ± 35.6

247.8 ± 24.2

0

27.2 ± 2.3

19.8 ± 2.9

27.0 ± 3.9

20.2 ± 2.5

3

27.5 ± 3.2

36.5 ± 2.0

29.8 ± 4.1

6

29.7 ± 2.9

19.7 ± 1.9
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23.5 ± 2.9

34.4 ± 2.8

26.9 ± 2.4

9

30.5 ± 3.9

21.6 ± 2.8

29.1 ± 3.6

29.9 ± 4.3

Total Energy
kcal)

Protein (g)

Total fat (g)

Carbohydrates (g)

Dietary Fiber (g)

Values are means ± SEM. Abbreviations used: NS-C: Nonsmokers control group; S-C: Smokers
control group; S-BB: smokers + 45 g blackberries/day; S-BL: smokers + 45 g blueberries/day.
NS-C: baseline: n=20, 3 mo. n=19, 6 mo. n= 19, and final n=18; S-C: baseline n=21, 3 mo. n=15,
6 mo. n= 12 and final n=12; S-BB: baseline n=8, 3 mo. n=6, 6 mo. n= 6 and final n=6; and S-BL
baseline n=16, 3 mo. n=14, 6 mo. n= 14 and final n=13 due to attrition.
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Appendix 6. Daily Intake of Selected Vitamins Calculated From a 7 D FFQ of Control
Smokers and Nonsmokers, and Smokers Consuming 45 g of Blackberries and Blueberries
at Baseline, 3, 6 and 9 Months.
Month

NS-C

S-C

S-BB

S-BL

0

200.6 ± 21.1

145.0 ± 29.2

143.1 ± 18.7

140.1 ± 15.8

3

185.5 ± 27.3

139.6 ± 19.6

235.8 ± 32.2

207.0 ± 30.4

6

202.2 ± 23.7

152.7 ± 28.1

185.9 ± 16.9

197.2 ± 26.0

9

174.9 ± 29.6

139.3 ± 9.5

174.3 ± 15.4

182.5 ± 23.1

0

1844.8 ± 212.1

1095.8 ± 156.2 1114.0 ± 402.7

3

1497.2 ± 158.6

Vitamin C
(mg)

Vitamin A
1162.6 ± 147.4

(RE)
906.184 ±
1122.8 ± 159.4

1108.0 ± 193.4

139.4
6

1712.0 ± 179.9

1071.8 ± 215.2 744.3 ± 142.2

891.4 ± 189.8

9

2010.0 ± 445.8

1220.3 ± 271.2 712.8 ± 230.6

963.9 ± 238.7

0

6.4 ± 0.9

4.4 ± 0.6

6.7 ± 1.2

4.3 ± 0.7

3

6.6 ± 0.9

5.2 ± 0.7

9.2 ± 2.1

6.0 ± 1.0

6

8.2 ± 1.5

4.6 ± 0.9

12.6 ± 2.8

7.4 ± 1.2

9

9.7 ± 1.6

6.2 ± 1.3

9.6 ± 2.6

8.1 ± 1.7

0

95.6 ± 15.8

75.8 ± 13.1

56.5 ± 14.8

90.8 ± 16.1

Vitamin E
(mg)

Vitamin K
(µg)
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3

85.8 ± 16.5

52.8 ± 5.9

59.7 ± 15.7

92.9± 36.1

6

88.6 ± 15.3

62.6 ± 17.7

49.3 ± 16.2

72.5 ± 20.6

9

70.6 ± 9.9

76.9 ± 17.2

56.37 ± 13.1

46.5± 12.0

0

3.8156 ± 0.7

3.8 ± 0.8

2.7 ± 0.7

1.7 ± 0.5

3

3.3128 ± 0.7

3.5 ± 0.9

2.7 ± 0.8

1.7± 0.4

6

3.9821 ± 0.8

3.6 ± 0.9

3.2 ± 1.0

1.2 ± 0.4

9

2.2758 ± 0.6

3.0 ± 0.7

1.7 ± 0.6

1.1 ± 0.3

Vitamin D
(ug)

Values are means ± SEM. Abbreviations used RE; retinol equivalents: NS-C: Nonsmokers
control group; S-C: Smokers control group; S-BB: smokers + 45 g blackberries/day; S-BL:
smokers + 45 g blueberries/day. NS-C: baseline: n=20, 3 mo. n=19, 6 mo. n= 19, and final n=18;
S-C: baseline n=21, 3 mo. n=15, 6 mo. n= 12 and final n=12; S-BB: baseline n=8, 3 mo. n=6, 6
mo. n= 6 and final n=6; and S-BL baseline n=16, 3 mo. n=14, 6 mo. n= 14 and final n=13 due to
attrition.
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Appendix 7. Daily Intake of Selected Minerals Calculated From a 7 D FFQ of
Control Smokers And Nonsmokers, and Smokers Consuming 45 g of Blackberries
and Blueberries at Baseline, 3, 6 And 9 Months.
Month
Ca (mg)

Mg (mg)

K(mg)

P (mg)

Na(mg)

NS-C

S-C

S-BB

S-BL

0

1066.9 ± 94.4

897.6 ± 111.2

821.8 ± 77.4

790.8 ± 73.1

3

1126.3 ± 172.3

801.2 ± 126.5

925.1 ± 77.2

787.2 ± 106.6

6

1017.6 ± 79.3

946.2 ± 159.6

810.8 ± 112.9

784.5 ± 125.6

9

913.5 ± 77.9

805.4 ± 126.8

760.7 ± 127.2

760.7 ± 97.5

0

411.6 ± 30.2

316.2 ± 34.03

428.2 ± 42.6

332.1 ± 29.7

3

414.1 ± 33.6

328.9 ± 34.0

437.2 ± 31.0

367.9 ± 46.1

6

442.8 ± 41.3

351.2 ± 43.3

434.1 ± 49.4

334.1 ± 23.1

9

420.8 ± 41.3

320.1 ± 42.5

348.3 ± 64.4

369.0 ± 31.9

0

4041.6 ± 284.5

3468.3 ± 318.1

3978.0 ± 260.7

3583.3 ± 283.5

3

4121.8 ± 363.7

3397.7 ± 387.8

4428.8 ± 301.0

3859.2 ± 449.9

6

4207.6 ± 303.0

3650.7 ± 498.7

4127.5 ± 388.4

3490.8 ± 288.1

9

4009.7 ± 342.4

3287.8 ± 454.7

3388.2 ± 599.5

3750.9 ± 347.3

0

1606.4 ± 102.3

1500.2 ± 185.4

1547.8 ± 125.1

1369.5 ± 134.0

3

1610.3 ± 147.7

1349.7 ± 152.2

1624.67 ± 81.2

1428.6 ± 220.1

6

1616.2 ± 124.6

1428.6 ± 199.1

1558.3 ± 187.6

1283.5 ± 108.6

9

1562.3 ± 121.0

1353.1 ± 191.2

1286.1± 259.4

1325.9 ± 123.4

0

2132.4 ± 178.8

1981.3 ± 289.2

2044.6 ± 243.2

2134.9 ± 237.9
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Biotin (µg)

3

1835.6 ± 186.6

2084.3 ± 322.1

2429.4 ± 137.5

1991.3 ± 232.5

6

2128.2 ± 265.3

2205.4 ± 476.1

2360.3 ± 399.7

1914.7 ± 140.5

9

2018.1 ± 198.5

2285.1 ± 298.0

1978.1 ± 334.6

1751.0 ± 255.6

0

21.7 ± 2.4

23.3 ± 7.0

12.6 ± 2.1

15.0 ± 1.5

3

23.4 ± 3.5

12.4 ± 2.9

16.0 ± 3.1

15.4 ± 2.2

6

25.2 ± 5.4

15.2 ± 2.7

13.3 ± 2.1

11.2 ± 1.9

9

19.0 ± 2.4

13.8 ± 2.5

14.3 ± 1.8

13.1 ± 1.9

Values represent least square means ± SEM. Abbreviations used: NS-C: Nonsmokers control
group; S-C: Smokers control group; S-BB: smokers + 45 g blackberries/day; S-BL: smokers +
45 g blueberries/day. NS-C: baseline: n=20, 3 mo. n=19, 6 mo. n= 19, and final n=18; S-C:
baseline n=21, 3 mo. n=15, 6 mo. n= 12 and final n=12; S-BB: baseline n=8, 3 mo. n=6, 6 mo.
n= 6 and final n=6; and S-BL baseline n=16, 3 mo. n=14, 6 mo. n= 14 and final n=13 due to
attrition.
.
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Appendix 8. Effects of freeze-dried blackberries and blueberries on bone biochemical
measurements in postmenopausal smokers

nmol DPD/mmol

Month

NS-C

S-C

S-BB

S-BL

p values

0

5.77 ± 0.40

7.16 ± 0.41

6.10 ± 0.75

8.14 ± 1.10

0.3415α

3

6.74 ± 0.64

6.30 ± 0.50

6.32 ± 0.33

8.02 ± 0.91

0.8273β

6

6.74 ± 0.39

6.87 ± 0.67

6.14 ± 0.54

6.36 ± 0.83

0.1229γ

9

6.57 ± 0.39

7.39 ± 0.62

6.12 ± 0.94

7.35 ± 0.46

0

29.45 ± 4.89 28.88 ± 1.90 25.56 ± 3.21

39.96 ± 3.02

0.3777α

3

31.28 ± 5.63 28.82 ± 2.21 24.67 ± 2.83

34.02 ± 2.42

0.5284β

6

30.92 ± 3.41 29.52 ± 2.34 30.37 ± 3.76

29.95 ± 2.42

0.0811γ

9

29.00 ± 3.11 29.32 ± 2.05 24.19 ± 2.44

32.72 ± 3.45

0

8.35 ± 1.13

9.14 ± 0.86 10.13 ± 1.64

9.37 ± 1.20

0.6848α

3

9.18 ± 1.27

9.30 ± 1.63

6.28 ± 2.25

11.18 ± 1.09

0.6146β

6

11.30 ± 1.06 10.62 ± 0.83 9.22 ± 1.77

8.34 ± 1.09

0.0521γ

9

10.12 ± 0.93 9.95 ± 1.37

9.43 ± 1.02

creatinine

BAP (U/L)

OC (ng/mL)

6.99 ± 1.52

Values represent means ± SEM. α, β, and γ represent, treatment, time, and treatment x time p
values respectively. NS-C: baseline: n=20, 3 mo. n=19, 6 mo. n= 19, and final n=18; S-C:
baseline n=21, 3 mo. n=15, 6 mo. n= 12 and final n=12; S-BB: baseline n=8, 3 mo. n=6, 6 mo.
n= 6 and final n=6; and S-BL baseline n=16, 3 mo. n=14, 6 mo. n= 14 and final n=13 due to
attrition. Abbreviations: NS-C: Nonsmokers control group; S-C: Smokers control group; S-BB:
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smokers + 45 g blackberries/day; S-BL: smokers + 45 g blueberries/day: BAP: bone alkaline
phosphatase; DPD: deoxypyridinoline; OC: osteocalcin
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Appendix 9. Effects of freeze-dried blackberries and blueberries on
biomarkers of oxidative stress and inflammation in postmenopausal smokers
Month
NS-C
S-C
S-BB
S-BL
p values
TBARS

hsCRP

0

10.46 ± 0.89

9.95 ± 0.61

11.77 ± 0.74 11.19 ± 1.10

0.5359 α

3

9.32 ± 0.82

12.44 ± 1.17 11.16 ± 1.25 10.58 ± 0.95

0.3396β

6

11.41 ± 1.17 13.51 ± 1.78 10.70 ± 0.92 13.21 ± 1.87

0.7531γ

9

13.26 ± 3.19 15.35 ± 2.60 10.94 ± 1.79 11.53 ± 1.06

0

1.54 ± 0.59

3.02 ± 0.53

2.97 ± 0.97

1.92 ± 0.67

0.1256α

3

1.00 ± 0.61

2.67 ± 0.62

2.56 ± 0.97

1.78 ± 0.66

0.1638 β

6

1.31 ± 0.59

3.03 ± 0.62

3.73 ± 1.01

2.30 ± 0.67

0.9905γ

9

1.12 ± 0.59

2.57 ± 0.64

2.41 ± 1.01

1.81 ± 0.67

Values represent means ± SEM. α, β, and γ represent treatment, time, and treatment x time p
values respectively. NS-C: baseline: n=20, 3 mo. n=19, 6 mo. n= 19, and final n=18; S-C:
baseline n=21, 3 mo. n=15, 6 mo. n= 12 and final n=12; S-BB: baseline n=8, 3 mo. n=6, 6 mo.
n= 6 and final n=6; and S-BL baseline n=16, 3 mo. n=14, 6 mo. n= 14 and final n=13 due to
attrition. Abbreviations: NS-C: Nonsmokers control group; S-C: Smokers control group; S-BB:
smokers + 45 g blackberries/day; S-BL: smokers + 45 g blueberries/day: TBARs: thiobarbituric
acid reactive substances; hsCRP: high-sensitivity C-reactive protein.
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